EP1748758A1 - Spot-on formulation useful for cosmetology and dermatology - Google Patents
Spot-on formulation useful for cosmetology and dermatologyInfo
- Publication number
- EP1748758A1 EP1748758A1 EP05770872A EP05770872A EP1748758A1 EP 1748758 A1 EP1748758 A1 EP 1748758A1 EP 05770872 A EP05770872 A EP 05770872A EP 05770872 A EP05770872 A EP 05770872A EP 1748758 A1 EP1748758 A1 EP 1748758A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- spot
- formulation
- acid
- chosen
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 126
- 238000009472 formulation Methods 0.000 title claims abstract description 100
- 239000004544 spot-on Substances 0.000 title claims abstract description 46
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 33
- 210000001732 sebaceous gland Anatomy 0.000 claims abstract description 29
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 28
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 27
- 150000003410 sphingosines Chemical class 0.000 claims abstract description 26
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 21
- 229940106189 ceramide Drugs 0.000 claims abstract description 21
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 21
- 239000011719 vitamin A Substances 0.000 claims abstract description 21
- 229940045997 vitamin a Drugs 0.000 claims abstract description 21
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 18
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 17
- 239000000194 fatty acid Substances 0.000 claims abstract description 17
- 229930195729 fatty acid Natural products 0.000 claims abstract description 17
- 239000003270 steroid hormone Substances 0.000 claims abstract description 17
- 150000001783 ceramides Chemical class 0.000 claims abstract description 15
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229940046009 vitamin E Drugs 0.000 claims abstract description 11
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 11
- 239000011709 vitamin E Substances 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 8
- 230000010415 tropism Effects 0.000 claims abstract description 5
- 210000003491 skin Anatomy 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 23
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 20
- 239000004480 active ingredient Substances 0.000 claims description 20
- 150000002632 lipids Chemical class 0.000 claims description 19
- 239000002243 precursor Substances 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 229960004232 linoleic acid Drugs 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 18
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 claims description 15
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims description 15
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 15
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 15
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 claims description 15
- 229940033329 phytosphingosine Drugs 0.000 claims description 15
- 229930002330 retinoic acid Natural products 0.000 claims description 15
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 14
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims description 14
- 229960001727 tretinoin Drugs 0.000 claims description 14
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 13
- 239000000839 emulsion Substances 0.000 claims description 12
- 235000004626 essential fatty acids Nutrition 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 12
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 10
- 206010000496 acne Diseases 0.000 claims description 10
- 230000029142 excretion Effects 0.000 claims description 10
- 210000004761 scalp Anatomy 0.000 claims description 10
- 230000000699 topical effect Effects 0.000 claims description 10
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims description 9
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 9
- 239000002537 cosmetic Substances 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims description 9
- 210000000434 stratum corneum Anatomy 0.000 claims description 9
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 229960004488 linolenic acid Drugs 0.000 claims description 8
- 229940108325 retinyl palmitate Drugs 0.000 claims description 8
- 235000019172 retinyl palmitate Nutrition 0.000 claims description 8
- 239000011769 retinyl palmitate Substances 0.000 claims description 8
- NTMFVGXTEGZVRI-RXQQAGQTSA-N (2s,3s,4r)-2-aminooctadecane-1,3,4-triol;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O.CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO NTMFVGXTEGZVRI-RXQQAGQTSA-N 0.000 claims description 7
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 7
- 235000013734 beta-carotene Nutrition 0.000 claims description 7
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 7
- 239000011648 beta-carotene Substances 0.000 claims description 7
- 229960002747 betacarotene Drugs 0.000 claims description 7
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 claims description 7
- 229940011871 estrogen Drugs 0.000 claims description 7
- 239000000262 estrogen Substances 0.000 claims description 7
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 7
- SZUJJDLBXJCDNT-ZCNNSNEGSA-N n-[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]acetamide Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(C)=O SZUJJDLBXJCDNT-ZCNNSNEGSA-N 0.000 claims description 7
- 239000000186 progesterone Substances 0.000 claims description 7
- 229960003387 progesterone Drugs 0.000 claims description 7
- 235000020945 retinal Nutrition 0.000 claims description 7
- 239000011604 retinal Substances 0.000 claims description 7
- 229960000342 retinol acetate Drugs 0.000 claims description 7
- 235000019173 retinyl acetate Nutrition 0.000 claims description 7
- 239000011770 retinyl acetate Substances 0.000 claims description 7
- OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 claims description 7
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims description 7
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 7
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 7
- GDKAAHDFPOWGQE-RXQQAGQTSA-N (2s,3s,4r)-2-aminooctadecane-1,3,4-triol;hydrochloride Chemical compound Cl.CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO GDKAAHDFPOWGQE-RXQQAGQTSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- 206010039792 Seborrhoea Diseases 0.000 claims description 6
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 6
- 230000006735 deficit Effects 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 229940035671 phytosphingosine hydrochloride Drugs 0.000 claims description 6
- 229960003471 retinol Drugs 0.000 claims description 6
- 235000020944 retinol Nutrition 0.000 claims description 6
- 239000011607 retinol Substances 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 229930003799 tocopherol Natural products 0.000 claims description 6
- 235000010384 tocopherol Nutrition 0.000 claims description 6
- 239000011732 tocopherol Substances 0.000 claims description 6
- 229960001295 tocopherol Drugs 0.000 claims description 6
- 201000004384 Alopecia Diseases 0.000 claims description 5
- 230000032683 aging Effects 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 claims description 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 4
- 206010016936 Folliculitis Diseases 0.000 claims description 4
- 206010020112 Hirsutism Diseases 0.000 claims description 4
- 206010064127 Solar lentigo Diseases 0.000 claims description 4
- 201000002996 androgenic alopecia Diseases 0.000 claims description 4
- 230000002225 anti-radical effect Effects 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims description 4
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 4
- 206010021198 ichthyosis Diseases 0.000 claims description 4
- 229940069445 licorice extract Drugs 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- NNNVXFKZMRGJPM-KHPPLWFESA-N sapienic acid Chemical compound CCCCCCCCC\C=C/CCCCC(O)=O NNNVXFKZMRGJPM-KHPPLWFESA-N 0.000 claims description 4
- 229940042585 tocopherol acetate Drugs 0.000 claims description 4
- LITUBCVUXPBCGA-WMZHIEFXSA-N Ascorbyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O LITUBCVUXPBCGA-WMZHIEFXSA-N 0.000 claims description 3
- 239000004261 Ascorbyl stearate Substances 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 3
- 206010040865 Skin hyperpigmentation Diseases 0.000 claims description 3
- 235000019276 ascorbyl stearate Nutrition 0.000 claims description 3
- 229940098330 gamma linoleic acid Drugs 0.000 claims description 3
- 208000000069 hyperpigmentation Diseases 0.000 claims description 3
- 229960005150 glycerol Drugs 0.000 claims description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical class OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 claims description 2
- 229940049918 linoleate Drugs 0.000 claims description 2
- 230000033764 rhythmic process Effects 0.000 claims description 2
- 239000012047 saturated solution Substances 0.000 claims description 2
- 150000003700 vitamin C derivatives Chemical class 0.000 claims description 2
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical class OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims 1
- 229940046836 anti-estrogen Drugs 0.000 claims 1
- 230000001833 anti-estrogenic effect Effects 0.000 claims 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- 238000003860 storage Methods 0.000 abstract description 7
- 239000003963 antioxidant agent Substances 0.000 abstract description 4
- 238000011200 topical administration Methods 0.000 abstract 1
- 210000002374 sebum Anatomy 0.000 description 17
- 235000020778 linoleic acid Nutrition 0.000 description 15
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 15
- 239000012071 phase Substances 0.000 description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- -1 esters Chemical class 0.000 description 8
- 239000004530 micro-emulsion Substances 0.000 description 8
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical class CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- 230000003325 follicular Effects 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 6
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 6
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 6
- 230000002280 anti-androgenic effect Effects 0.000 description 6
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 6
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 6
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000000051 antiandrogen Substances 0.000 description 5
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000004064 cosurfactant Substances 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000003495 polar organic solvent Substances 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 235000021319 Palmitoleic acid Nutrition 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 229960001334 corticosteroids Drugs 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229940061720 alpha hydroxy acid Drugs 0.000 description 3
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000003093 cationic surfactant Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 229960004125 ketoconazole Drugs 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- SGTYQWGEVAMVKB-NXCFDTQHSA-N [(2s,3s,4r)-2-acetamido-3,4-diacetyloxyoctadecyl] acetate Chemical compound CCCCCCCCCCCCCC[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](NC(C)=O)COC(C)=O SGTYQWGEVAMVKB-NXCFDTQHSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical class [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- URJOWNUVTORLNY-UHFFFAOYSA-N (5-hexadecanoyloxy-4-oxopyran-2-yl) hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC1=CC(=O)C(OC(=O)CCCCCCCCCCCCCCC)=CO1 URJOWNUVTORLNY-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WITMXBRCQWOZPX-UHFFFAOYSA-N 1-phenylpyrazole Chemical class C1=CC=NN1C1=CC=CC=C1 WITMXBRCQWOZPX-UHFFFAOYSA-N 0.000 description 1
- KBHSAMYHDBBRKS-QTJGBDASSA-N 2-hydroxy-n-[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]benzamide Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)C1=CC=CC=C1O KBHSAMYHDBBRKS-QTJGBDASSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- HBZVNWNSRNTWPS-UHFFFAOYSA-N 6-amino-4-hydroxynaphthalene-2-sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C(O)C2=CC(N)=CC=C21 HBZVNWNSRNTWPS-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229940088990 ammonium stearate Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical compound [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- DAMJCWMGELCIMI-UHFFFAOYSA-N benzyl n-(2-oxopyrrolidin-3-yl)carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1CCNC1=O DAMJCWMGELCIMI-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 1
- 229960003843 cyproterone Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001496 desquamative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000002323 endectocidal effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 1
- 229940093767 glabridin Drugs 0.000 description 1
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 1
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- RNYJXPUAFDFIQJ-UHFFFAOYSA-N hydron;octadecan-1-amine;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[NH3+] RNYJXPUAFDFIQJ-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 206010024217 lentigo Diseases 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 230000002248 lipoperoxidative effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- ZHALDANPYXAMJF-UHFFFAOYSA-N octadecanoate;tris(2-hydroxyethyl)azanium Chemical compound OCC[NH+](CCO)CCO.CCCCCCCCCCCCCCCCCC([O-])=O ZHALDANPYXAMJF-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229940104257 polyglyceryl-6-dioleate Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229910002059 quaternary alloy Inorganic materials 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 125000000946 retinyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 229940077859 salicyloyl phytosphingosine Drugs 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 210000004378 sebocyte Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000008491 skin homeostasis Effects 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940080236 sodium cetyl sulfate Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940080350 sodium stearate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- ITCAUAYQCALGGV-XTICBAGASA-M sodium;(1r,4ar,4br,10ar)-1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylate Chemical compound [Na+].C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C([O-])=O ITCAUAYQCALGGV-XTICBAGASA-M 0.000 description 1
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 150000003421 squalenes Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940029614 triethanolamine stearate Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 208000016254 weariness Diseases 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
Definitions
- the present invention relates to a new formulation with sebaceous tropism for localized topical application, useful in the field of cosmetology and dermatology, its use in cosmetics and dermatology as well as the associated cosmetic treatment methods.
- the sebaceous gland has long been considered by many authors as a fossil gland with the sole function of producing sebum and being involved in the pathophysiology of acne.
- the sebaceous gland is part of a larger, more complex system, the pilosebaceous unit which includes the hair follicle, the excretion canal and the gland itself. This unit reaches its full development in the post-pubertal period under
- the sebaceous gland therefore appears as a true secondary sexual organ capable of not only metabolizing a wide variety of androgens, but also, thanks to equipment
- tiu ⁇ the holocrine secretion-production of sebum at the end of a 15-day cell cycle leading to the lysis of sebocytes, - the discharge of sebum within the infundibulum of the sebaceous unit, - regular excretion at the surface of the skin and on the hair (100 to 500 ⁇ g / cm 2 ); it is a real reservoir.
- the sebum is composed of squalene (15%), waxes (25%) and triglycerides (60%) with completely specific fatty acid chains, genetically determined in their proportions for each individual. The originality of the sebaceous gland in lipid synthesis should therefore be emphasized.
- Sebum because of its composition, can be considered as an oil in the physicochemical sense, which indicates a notable influence of the temperature on its flow.
- the role of sebum is becoming better known. It is involved in the organization of lipids within the stratum corneum and therefore participates in the barrier effect. Waxes reinforce the impermeability of the skin surface. Squalenes participate in UV protection like certain cyto ines which are spilled on its surface.
- the specific lipids of sebum thanks to the action of an endogenous ⁇ -desaturase play a role in the modulation of inflammation.
- sebum constitutes the only route of excretion of vitamin E, that, by its supply of glycerol, it participates in skin hydration and, lastly, that it participates in the regulation of the ecosystem. (anti gram + activity of palmitoleic acid isomers).
- the anatomical position of the pilosebaceous unit places the follicular reservoir at the crossroads of two worlds: one internal and living, the other as an environment carrying germs and oxygen. This explains the constant transformation of the sebum excreted from its storage area, subsequently called the follicular reservoir.
- Patent GB 2004 741 relates to a composition for the treatment of alopecia, based on cholesterol, fatty acids and a phospho-aminolipid.
- the patent FR 2795960 is based on the observation that certain fatty acids can have a relaxing effect on the body, and it describes a stable microemulsion based on fatty acids with free carboxylic acid group which can be administered orally, injectable, topical, etc., for the treatment of anxiety.
- Another emulsion based on fatty acids is described in US Pat. No. 6,361,806, but this formulation is intended to cross the epidermis.
- Patent DE 4113346 describes an aqueous hair composition based on phospholipids, oils and alcohols.
- compositions described in the art are suitable for using the properties of the sebaceous glands.
- Cosmetological or dermatological treatments are often very restrictive and can then lead to a phenomenon of weariness in the patient when the desired improvements are considered too slow to appear.
- the studies carried out by the applicant have shown that it is possible to use the storage capacity that constitutes the sebaceous gland, and more particularly the follicular reservoir, to release lipophilic active ingredients for a prolonged period.
- the vehicle must be compatible with human sebum, present no risk of modifying its physicochemical properties, and be chosen so as to be preferentially absorbed at the level of the sebaceous gland.
- the present invention therefore relates to a formulation for localized topical application, comprising an emulsion or saturated solution containing one or more lipophilic active principles, preferably lipidic, in a mixture of solvents comprising one or more unsaturated fatty acids in C 4 -C 26 and a polar liquid vehicle, with sebaceous tropism.
- the liquid vehicle preferably comprises a polar organic solvent.
- the unsaturated C 4 -C 26 fatty acid may contain from 1 to 6 unsaturations, and preferably from 1 to 6 double bonds. It can for example be chosen from butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, acid stearic, oleic acid, sapienic acid, ricinoleic acid, ⁇ - and ⁇ -linoleic acid, ⁇ - and ⁇ -linolenic acid, steraidonic acid, arachidic acid and acid behenic. These fatty acids can be used individually or as a mixture between them. Sapienic acid is naturally found in abundance in the sebaceous gland in humans.
- fatty acid is a monounsaturated fatty acid having 16 carbon atoms and a single cis double bond at the 6th carbon from the carboxyl terminus.
- the fatty acid and the active principle are preferably dissolved in an organic solvent to ensure preferential absorption in the sebaceous gland. Mention may be made, as preferred fatty acid, of sapienic acid, linolenic acid and linoleic acid. Linoleic acid, more precisely ⁇ - or ⁇ -linoleic acid, is preferred.
- the present invention relates to a sebaceous tropism formulation which can advantageously be in the form of a simple solution, preferably anhydrous, or of a simple emulsion or of an emulsion of quaternary type, saturated with active principle.
- a simple anhydrous oily solution saturated with active principle
- the vehicle is essentially composed of fatty acid and a polar organic solvent.
- the polar liquid vehicle is a quaternary system comprising a hydrophilic phase, an oily phase, a surfactant and a cosurfactant.
- Such a microemulsion is liquid, translucent, and isotropic.
- the formulation optionally contains a crystallization inhibitor and / or an antioxidant and / or any other excipient compatible with the mode of administration used according to the present invention, as detailed below.
- a “formulation for localized topical application” is also commonly called a “Spot-on” type formulation; the two terminologies can be used interchangeably in the context of the present invention; they mean that they are intended to treat, by means of a targeted application of the active principle, precise cutaneous zones, prone to a particular affection of the skin.
- This type of formulation is characterized by the fact that the application of a single dose, typically of a single drop, without spreading, of said formulation to the skin allows, thanks to a phenomenon of dispersal, reaching a large amount of sebaceous glands from the affected area.
- a spot-on formulation containing a combination of 1-N-phenylpyrazoles and endectocidal macrocyclic lactones, useful for combating parasites in the field of veterinary medicine is described in US Pat. No. 6,426,333.
- the active principle is stored in the sebaceous glands, and more particularly in the follicular reservoir, then gradually released into the sebaceous flow on the stratum corneum, according to the rhythm physiological excretion of the sebaceous glands.
- the formulation according to the present invention has in particular the advantage of allowing easy incorporation of the lipophilic active principle into the follicular reservoir of the pilosebaceous unit and then of allowing not only a regular distribution of the active principle on the skin but also a release. spread over time of the active ingredient. In this way, the active ingredient can then exert a targeted action on the skin at the level of the stratum corneum.
- the formulations according to the present invention do not target the passage of the skin barrier. In other words, the passage through the blood is very limited.
- the cosmetic and / or dermatological treatment objectives vary depending on the active ingredient used.
- the sebaceous glands are used exclusively as a storage reservoir for a slow release of the active principle at the level of the stratum corneum. This is the case, for example, when the active principle is a ceramide or one of its precursors, as indicated below.
- the deficit in sebaceous secretion can come from aging of the skin and result from localized atrophy conditions; excess, that is to say seborrhea, can be a source of acne or inflammatory dermatitis such as seborrheic dermatitis.
- the active ingredients suitable for the formulation Any active ingredient having lipophilic properties can be used, and preferably a lipid active ingredient.
- lipophilic active principles suitable for the formulation according to the present invention: any fat-soluble vitamin, such as vitamin A and its derivatives, vitamin E and its derivatives; any lipophilic anti-radical agent; ceramides or their sphingoid base type precursors such as sphingosine or phytosphingosine; steroid hormones, such as estrogen or progesterone, and essential fatty acids, such as linoleic acid and linolenic acid.
- any fat-soluble vitamin such as vitamin A and its derivatives, vitamin E and its derivatives
- any lipophilic anti-radical agent such as ceramides or their sphingoid base type precursors such as sphingosine or phytosphingosine
- steroid hormones such as estrogen or progesterone
- essential fatty acids such as linoleic acid and linolenic acid.
- Vitamin A also known under the name of retinol, is a substance extremely used in cosmetology in particular because of its major physiological function, particularly in the regulation proliferation and differentiation of a number of cell types. It is known in particular that the topical application of retinol stabilizes the balance of vitamin A in the skin and that this balance can be altered in particular by exposure to UV light. Thus, vitamin A deficiency leads in particular to an increase in the formation of wrinkles, especially in the event of overexposure to the sun ("photoaging"). Insufficient vitamin A also leads to a loss of skin elasticity and weakens the barrier function of the skin against microorganisms. Finally, retinol is commonly used in the treatment of acne.
- vitamin A can be used in its natural form (retinol) or in the form of its acid (retinoic acid) or alternatively retinyl acetate, retinaldehyde, ⁇ -carotene or retinyl palmitate, in the context of the present invention.
- Vitamin E and its derivatives are substances which, by virtue of their presumed properties as anti-free radicals (free radical suppressants), are widely used in cosmetology and dermatology.
- Vitamin E, also called tocopherol can advantageously be incorporated into the formulation according to the present invention pure (natural form) or in the form of an ester and in particular in the form of tocopherol acetate, tocopherol linoleate or tocopherol succinate .
- lipophilic anti-radical agent of lipoic acid derivatives, andrographolides, of lipophilic vitamin C derivatives such as esters, for example palmitate and ascorbyl stearate.
- lipophilic vitamin C derivatives such as esters, for example palmitate and ascorbyl stearate.
- the sphingoid bases used in the formulations of the present invention can be obtained by known methods from various suitable sources, for example from natural sources or by chemical synthesis or by fermentation. Chemical synthesis methods are generally relatively expensive and do not always make it possible to obtain the sphingoid bases having the desired stereochemical configurations.
- the sphingoid bases can also be obtained from animal or plant tissues by extraction and purification, but these methods are generally Lely expensive and animal sources do not always have the desired bacteriological qualities.
- the sphingoid bases used in the invention are preferably prepared by microbial fermentation, for example from a yeast such as Pichia cifieri, and the phytosphingosine obtained in this way has the advantage of being very close to that of the animal's skin.
- the phytosphigosine obtained from tetra-acetyl-phytosphingosine (TAPS) derived from Pichia ciferii by deacetylation is used as the sphingoid base.
- the deacetylation reaction can be carried out by chemical reaction, for example by hydrolysis in the presence of potassium hydroxide, or by enzymatic reaction.
- the sphingoid base is advantageously chosen from sphingosine, sphinganine, phytosphingosine, tetracetylphytosphingosine, N-acetylphytosphingosine, phytosphingosine hydrochloride and phytosphingosine salicylate.
- Steroid hormones such as estrogens, antiandrogens or progesterone are known for their ability to combat certain forms of seborrhea, Fox and Fordyce disease, androgenic alopecia, acne and hirsutism.
- the components of the formulation can be presented either in the form of a simple oily solution, or in the form of a simple or quaternary emulsion, the formulation being in both cases saturated with lipid active principle. It comprises, in addition to the fatty acid, a polar organic solvent which can be any polar organic solvent generally acceptable in a formulation for topical application, known to those skilled in the art.
- polar organic solvents acetone, ethyl acetate, methanol, ethanol, isopropanol, dimethylformamide, diethylene glycol, dichloromethane, monoethyl ether of diethylene glycol (Transcutol) can be used in particular. ).
- a solvent capable of facilitating or improving the penetration of the active ingredients into the skin can also be advantageously used in the compositions of the invention, and for example a non-ionic amphiphilic glycerol derivative such as 1, 2-O -isopropylidene glycerol (Solketal).
- solvents can be supplemented with various excipients depending on the nature of the phases desired, such as the caprylic triglyceride / C8-C10 caprate (Estasan or Miglyol 812), or oleic acid.
- use is preferably made of Transcutol and Solketal, known for their high non-selective lipophilicity.
- a volatile cosolvent can advantageously be associated with the main solvent, and for example an alcohol such as ethanol and glycol, to facilitate drying after application, and cause oversaturation of the active principle.
- the formulation comprises an oily phase and a hydrophilic phase.
- This cosolvent can be non-polar and be constituted for example by linoleic acid.
- the anhydrous nature of the composition of the invention promotes its stability over time.
- an aqueous phase may be present but the water does not represent more than 5% by weight relative to the total weight of the composition.
- the oily phase is formed by the lipophilic active principle dissolved in the unsaturated fatty acid (s) in CC 26 , optionally supplemented with mineral oils or vegetable oils, unsaturated polyglycosylated glycerides or triglycerides, or alternatively mixtures of such compounds.
- the hydrophilic phase can in particular be formed from glycol derivatives in general, such as propylene glycol, glycol ethers, polyethylene glycols or glycerol.
- Propylene glycol, diethylene glycol, monoethyl ether of diethylene glycol and monoethyl ether of dipropylene glycol are particularly preferred.
- the surface-active agents for the microemulsion can be chosen from monoethyl ether of diethylene glycol, monomethyl ether of dipropylene glycol, polyglycolysed C ⁇ -Cio glycerides and polyglyceryl 6-dioleate. More particularly when the formulation according to the present invention is in the form of a microemulsion, it is characterized by a stable dispersion of micro-droplets of the oily phase in the aqueous phase, or conversely of micro-droplets of the aqueous phase in the oily phase.
- the size of these micro-droplets is less than 200 nm (1,000 to 100,000 nm for emulsions).
- the interfacial film consists of an alternation of surfactant molecules (TA) and Co-surfactants (CoTa) which, by lowering the interfacial tension, allow the spontaneous formation of the microemulsion.
- TA surfactant molecules
- CoTa Co-surfactants
- the oily phase is present in a content which can be between 2 and 15%, more particularly between 7 and 10%, and preferably between 8 and 9% relative to the total volume of the formulation.
- the aqueous phase is present in a content which can be between 1 and 4% relative to the total volume of the formulation.
- the microemulsion preferably contains from 25 to 75% surfactant and 10 to 55% cosurfactant relative to the total volume of the formulation.
- the cosurfactant to surfactant ratio is preferably between 1/7 and 1/2.
- the cosurfactants can be chosen from short-chain alcohols, such as ethanol and glycol. Some compounds are common to the three components discussed above, ie, hydrophilic phase, surfactant and cosurfactant.
- the crystallization inhibitor can prove to be very advantageous when there is a risk of crystallization of an active principle. It is then useful so that the active principle reaches the follicular reservoir easily, but also so that the release phase is facilitated, that is to say so that the active principle is effectively soluble in the sebum.
- the crystallization inhibitor can in particular be present in a content of 1 to 20% by weight relative to the total volume of the formulation, preferably from 5 to 15%.
- the crystallization inhibitors which can be used in the invention include: - polyvinylpyrrolidone (PVP), polyvinyl alcohols, copolymers of vinyl acetate and of vinyl pyrrolidone, polyethylene glycols, benzyl alcohol, mannitol, glycerol, sorbitol, polyoxyethylene sorbitan esters; lecithin, sodium carboxymethyl cellulose; acrylic derivatives such as methacrylates and others; - anionic surfactants, such as alkali stearates, in particular sodium stearate, potassium stearate or ammonium stearate; calcium stearate, triethanolamine stearate; sodium abietate; alkyl sulfates, in particular sodium lauryl sulfate and sodium cetyl sulfate; dodecy
- the formulation may also include an antioxidant intended to avoid any lipoperoxidation, this agent being in particular present in a content of between 0.005 to 1% (W / V), preferably between 0.01 to 0.05%.
- Any conventional antioxidant can be used for those skilled in the art. Mention may in particular be made of butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), ascorbic acid, sodium metabisulfite, propyl gallate, sodium thiosulfate or a mixture of not more than two of them.
- BHA butylhydroxyanisole
- BHT butylhydroxytoluene
- ascorbic acid sodium metabisulfite
- propyl gallate sodium thiosulfate or a mixture of not more than two of them.
- the components described above, useful for preparing the liquid vehicle of the formulation according to the present invention are well known to those skilled in the art and can be obtained commercially or by known techniques.
- the formulations according to the present invention are generally prepared by the
- the formulations according to the invention are extremely effective for long periods of time in the various treatments described above.
- the formulations according to the present invention can be packaged in bottles with suitable applicators.
- the formulation can be applied in the form of one or more drops to be distributed over the areas to be treated.
- the dosage is adapted according to the active ingredient used and the condition to be treated. For example, it can be between 10 and 25 drops applied to the face, in the case of retinoic acid in 0.5% solution.
- the flow of the sebum excretion phase depends on the temperature. This parameter can be advantageously used when seeking to administer a lipophilic anti-radical agent.
- the invention relates to a method of cosmetic treatment of the skin intended for the treatment or prevention of skin damage associated with aging of the skin which may consist of a loss of firmness of the skin, of the skin tone and the appearance of fine lines and wrinkles, consisting in applying to the affected areas of the skin a formulation according to the present invention containing vitamin A, for example in the form of retinyl acetate, retinyl palmitate, retinoic acid, retinaldehyde or ⁇ -carotene.
- vitamin A for example in the form of retinyl acetate, retinyl palmitate, retinoic acid, retinaldehyde or ⁇ -carotene.
- the invention also relates to a cosmetic treatment method for the skin intended for the treatment or prevention of skin damage associated with photoaging of the skin, comprising applying to the affected areas of the skin a formulation according to the present invention containing vitamin A, for example in the form of retinyl acetate, retinyl palmitate, retinoic acid, retinaldehyde or ⁇ -carotene, vitamin E, for example in the form of tocopherol acetate or tocopherol succinate, or any lipophilic anti-free radical agent, for example in the form of lipoic acid, andro-grapholides, esters of vitamin C such as palmitate and ascorbyl stearate.
- vitamin A for example in the form of retinyl acetate, retinyl palmitate, retinoic acid, retinaldehyde or ⁇ -carotene
- vitamin E for example in the form of tocopherol acetate or tocopherol succinate
- any lipophilic anti-free radical agent for
- the invention relates to a method of cosmetic treatment of the skin intended for exfoliation or peeling thereof, consisting in applying to the skin a formulation according to the present invention containing concentrated retinoic acid, preferably between 0, 1 and 1%.
- the invention relates to a spot-on type formulation according to the present invention for its use as a dermatological composition for human medicine.
- the invention relates to: - a spot-on type formulation according to the present invention, comprising vitamin A, a steroid hormone dienne, a ceramide or one of its precursors of sphingoid base type or else an essential fatty acid, for its use as a dermatological composition intended for treating acne, - a formulation of spot-on type according to the present invention, comprising a ceramide or one of its precursors of sphingoid base type or else a steroid hormone, for its use as a dermatological composition intended for treating seborrhea, - a formulation of spot-on type according to the present invention, comprising a ceramide or one of its sphingoid base precursors or an essential fatty acid, for its use as a dermatological composition intended for treating seborrheic dermatitis, - a formulation of spot-on type according to the present invention, comprising vitamin E , vitamin A or glycerol, for its use as a dermatological composition intended to treat se
- a spot-on type formulation comprising a kojic acid ester, a licorice extract, a steroid hormone, vitamin A or else a ceramide or one of its sphingoid base type precursors, for its use as a dermatological composition intended to treat actinic lentigos, pigmentary disorders linked to aging and hypermelanosis.
- the invention relates to the use of a lipophilic active principle for cutaneous use for the preparation of a formulation for localized topical application in humans, intended to be absorbed by the sebaceous glands and then gradually released into the time by the latter on the stra tum corneum, according to its secretory flow.
- the invention relates to the use of an active principle chosen from vitamin A, for example in pure form (retinol) or in the form of retinyl acetate, palmitate or retinyl of retinoic acid, retinaldehyde or ⁇ - carotene; steroid hormones, for example estrogens, progesterone and antiandrogens; ceramides or their precursors such as sphingoid bases, for example sphingosine, sphinganine, phytosphingosine, tetracetylphytosphingosine, N-acetylphytosphingosine, phytosphingosine hydrochloride and phytosphingosine salicylate; essential fatty acids, for example linoleic acid and linolenic acid, for the preparation of a formulation according to the present invention, intended for treating acne.
- vitamin A for example in pure form (retinol) or in the form of retinyl acetate
- the invention relates to the use of an active principle chosen from ceramides or their precursors such as sphingoid bases, for example sphingosine, sphinganine, phytosphingosine, tetracetylphytosphingosine, N-acetylphytosphingosine, hydrochloride phytosphingosine and phytosphingosine salicylate; steroid hormones such as estrogen, progesterone or antiandrogens, for the preparation of a formulation according to the present invention, intended for treating seborrhea.
- ceramides or their precursors such as sphingoid bases, for example sphingosine, sphinganine, phytosphingosine, tetracetylphytosphingosine, N-acetylphytosphingosine, hydrochloride phytosphingosine and phytosphingosine salicylate; steroid hormones such as estrogen, progesterone or anti
- the invention also relates to the use of an active principle chosen from ceramides or their precursors such as a sphingoid base, for example sphingosine, sphinganine, phytosphingosine, tetracetylphytosphingosine, N-acetylphytosphingosine, phytosphingosine hydrochloride and phytosphingosine salicylate; essential fatty acids, for example linoleic acid and linolenic acid, for the preparation of a formulation according to the present invention, intended for treating seborrheic dermatitis.
- ceramides or their precursors such as a sphingoid base, for example sphingosine, sphinganine, phytosphingosine, tetracetylphytosphingosine, N-acetylphytosphingosine, phytosphingosine hydrochloride and phytosphingosine salicylate; essential fatty
- the invention relates to the use of an active ingredient chosen from vitamin E, for example tocopherol acetate, tocopherol succinate; vitamin A, for example retinyl acetate, retinyl palmitate, retinoic acid, retinaldehyde or ⁇ -carotene and glycerol, for the preparation of a formulation according to the present invention, intended for treating deficit sebaceous.
- vitamin E for example tocopherol acetate, tocopherol succinate
- vitamin A for example retinyl acetate, retinyl palmitate, retinoic acid, retinaldehyde or ⁇ -carotene and glycerol
- Another subject of the invention is the use of an active principle chosen from steroid hormones, for example estrogens, progesterone or antiandrogens such as cyproterone or finasteride, for the preparation of a formulation according to the present invention , intended to treat Fox and Fordyce disease, androgenic alopecia or hirsutism.
- steroid hormones for example estrogens, progesterone or antiandrogens such as cyproterone or finasteride
- the invention finally relates to the use of an active principle chosen from ceramides or their precursors such as a sphingoid base, for example sphingosine, sphinganine, phytosphingosine, tetracetylphytosphingosine, N-acetylphytosphingosine, hydrochloride of phytosphingosine and phytosphingosine salicylate, for the preparation of a formulation according to the present invention, intended for treating chronic folliculitis of the scalp.
- a sphingoid base for example sphingosine, sphinganine, phytosphingosine, tetracetylphytosphingosine, N-acetylphytosphingosine, hydrochloride of phytosphingosine and phytosphingosine salicylate, for the preparation of a formulation according to the present invention, intended for treating chronic folliculitis of the scalp.
- the subject of the invention is the use of an active principle chosen from essential fatty acids, for example linoleic acid and linolenic acid, for the preparation of a formulation according to the present invention, intended for treating ichthyosis in its location of the scalp.
- an active principle chosen from essential fatty acids, for example linoleic acid and linolenic acid, for the preparation of a formulation according to the present invention, intended for treating ichthyosis in its location of the scalp.
- the subject of the invention is the use of an active ingredient chosen from kojic acid esters, for example kojic acid dipalmitate; licorice extracts (glabridin); steroid hormones, for example estrogens, progesterone and antiandrogens; vitamin A, for example retinyl acetate, retinyl palmitate, retinoic acid, retinaldehyde and ⁇ -carotene; ceramides or their precursors such as a sphingoid base, for example sphingosine, sphinganine, phytosphingosine, tetracetylphytosphingosine, N-acetylphytosphingosine, phytosphingosine hydrochloride and phytosphingosine salicylate, intended for treating actinic lentigos pigmentary disorders linked to aging and hypermelanosis.
- kojic acid esters for example kojic acid dipalmitate
- Example 1 Study Protocol and Result (10 Cases) for Vitamin A This first example aims to illustrate the relevance of the concept of administration of lipophilic active principles in the follicular reservoirs before their prolonged release, according to the cycle physiological. To affirm this concept:
- PREPARATION Vitamin A palmitate 3,000,000 IU BHT 0.10 g PVP 4 g BHA 0.20 g Sodium fluoresceinate 020 g (or nile red 0.20 g) Linoleic acid 5 g Diethylene glycol QS 100 g WITNESS: Sodium Fluoresceinate 0.20 g Alcohol 60 ° QS 100 g
- CHOICE OF APPLICATION SITES Region rich in sebaceous glands: above-mentioned fold, nasogenic fold
- PROTOCOL A comparative study was carried out on symmetrical zones. A drop of 0.4 ml of the product to be studied was deposited on each zone retained. Natural drying was carried out without spreading. We studied - the dispersion by measuring the area covered after 15 minutes - the absorption by degree of fluorescence at 60 minutes and 6 hours - the afterglow by measuring the fluorescence at 24 hours, 48 hours, 96 hours. At the 168 th hour, the toilet of the skin or the scalp was done normally while avoiding too powerful surfactants. A surgras toilet roll and a mild shampoo were recommended. The extinction of fluorescence has also been studied. The active has been demonstrated by stripping the epidermis and specific coloring with antimony trichloride which gives a blue coloring under microscopy at 24 hours and 96 hours. Finally, we studied the absorption spectrum (characteristic band at 328 nanometers).
- the results are identical in all subjects.
- the dispersion is better on the hairy areas and on the areas rich in sebaceous glands, it is in all cases greater than the control.
- the absorption is identifiable from the first hour with a dotted line at the level of the dispersion spot corresponding to the pilosebaceous orifices. This dotted line is not found at the witness level.
- This aspect is amplified at the 6 th hour while the fluorescence of the control spot decreases.
- the remanence is confirmed by a clear persistence of the fluorescence which is still observed at the 168 th hour. There is a total disappearance of the control spot, the remanence is greater on the areas rich in sebaceous glands.
- Example 2 Retinoic acid formulation in a formulation according to the invention Retinoic acid 0.30 g BHT 0.10 g BHA 0.20 g Linoleic acid 5.00 g PVP 4.00 g Transcutol QS 100 g
- Example 3 Other examples of formulations according to the invention and results after treatment Other examples have been carried out to illustrate the variety of treatments which can be envisaged by means of the formulations according to the present invention. Spot-on based on linoleic acid 2 applications per week to treat retentional acne. Aim: correction of deficits in linoleic acid in the sebum of acne patients. The results have been very positive.
- Linoleic acid 5.0 G Tocopherol 0.5 G BHT 0.1 G BHA 0.2 G TWEEN 80 10.0 G Isopropanol 40 ML Diethylene glycol QS 100 ML There is a normalization of the desquamative state.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a novel formulation useful for cosmetology and dermatology by using the storage capacity of sebaceous glands. The inventive spot-on formulation contains an active lipophilic principle selected from the vitamin A and E, a lipophilic antioxidant agent, ceramides or sphingoid bases and steroid hormones associated with one or several fatty acids unsaturated in C4-C26 and a liquid vehicle having sebaceous tropism. The inventive formulation is usable for local topical administration of the active lipophilic principles.
Description
FORMULATION DE TYPE SPOT-ON UTILE EN COSMETOLOGIE ET EN DERMATOLOGIE. SPOT-ON FORMULATION USEFUL IN COSMETOLOGY AND DERMATOLOGY.
La présente invention concerne une nouvelle formulation à tropisme sébacé pour l'application topique localisée, utile dans le domaine de la cosmétologie et de la dermatologie, son utilisation en cosmétique et en dermatologie ainsi que les 5 méthodes de traitement cosmétique associées. La glande sébacée a longtemps été considérée par beaucoup d'auteurs comme une glande fossile n'ayant comme fonction que de produire du sébum et d'être en cause dans la physio- pathologie de l'acné.The present invention relates to a new formulation with sebaceous tropism for localized topical application, useful in the field of cosmetology and dermatology, its use in cosmetics and dermatology as well as the associated cosmetic treatment methods. The sebaceous gland has long been considered by many authors as a fossil gland with the sole function of producing sebum and being involved in the pathophysiology of acne.
L0 Ces dix dernières années la recherche s'est à nouveau intéressée à ce problème, ce qui a permis de réviser le jugement péjoratif initial. A la lumière de ces travaux, des précisions ont pu être apportées sur le rôle important que joue la glande sébacéeL0 Over the past ten years research has again become interested in this problem, which has made it possible to revise the initial derogatory judgment. In the light of this work, clarifications could be made on the important role played by the sebaceous gland
L5 dans 1 ' homéostasie cutanée. La glande sébacée est partie intégrante d'un système plus large, plus complexe, l'unité pilosébacée qui comprend le follicule pilaire, le canal d'excrétion et la glande elle-même. Cette unité atteint son plein développement dans la période post-pubertaire sousL5 in skin homeostasis. The sebaceous gland is part of a larger, more complex system, the pilosebaceous unit which includes the hair follicle, the excretion canal and the gland itself. This unit reaches its full development in the post-pubertal period under
.0 l'influence des sécrétions hormonales surrénaliennes et gonadiques . La glande sébacée apparaît donc comme un véritable organe sexuel secondaire capable non seulement de métaboliser une grande variété d' androgènes, mais aussi, grâce à un équipement.0 the influence of adrenal and gonadal hormonal secretions. The sebaceous gland therefore appears as a true secondary sexual organ capable of not only metabolizing a wide variety of androgens, but also, thanks to equipment
_5 enzymatique spécifique, d'utiliser le cholestérol comme substrat pour la synthèse des précurseurs androgènes. De plus sa richesse en 5 -réductase permet une utilisation efficace de la testostérone . D'autres récepteurs hormonaux sont également présents (rétinoïdes, thyroïde, vitamine D) qui régulent son_5 specific enzyme, to use cholesterol as a substrate for the synthesis of androgen precursors. In addition, its richness in 5-reductase allows effective use of testosterone. Other hormone receptors are also present (retinoids, thyroid, vitamin D) which regulate its
30 activité physiologique. Trois événements successifs la caractérisent :30 physiological activity. Three successive events characterize it:
tiu ϋ
- la sécrétion-production holocrine de sébum au terme d'un cycle cellulaire de 15 jours aboutissant à la lyse des sébocytes, - le déversement du sébum au sein de 1 ' infundibulum de l'unité sébacée, - l'excrétion régulière à la surface de la peau et au niveau des cheveux (100 à 500 μg/cm2) ; il s'agit d'un véritable réservoir. Le sébum est composé de squalène (15%), de cires (25%) et de triglycérides (60%) avec des chaînes d'acides gras tout à fait spécifiques, génétiquement déterminés dans leurs proportions pour chaque individu. L'originalité de la glande sébacée dans la synthèse lipidique est donc à souligner. Le sébum, du fait de sa composition, peut être considéré comme une huile au sens physicochimique, ce qui indique une influence notable de la température sur son écoulement. Le rôle du sébum est de mieux en mieux connu. Il intervient dans l'organisation des lipides au sein de la couche cornée et participe donc à l'effet barrière. Les cires renforcent l'imperméabilité de la surface de la peau. Les squalènes participent à la protection UV comme certaines cyto ines qui sont déversées à sa surface. Enfin, les lipides spécifiques du sébum, grâce à l'action d'une β-désaturase endogène jouent un rôle dans la modulation de l'inflammation. De plus, une régulation spécifique des neuropeptidestiu ϋ - the holocrine secretion-production of sebum at the end of a 15-day cell cycle leading to the lysis of sebocytes, - the discharge of sebum within the infundibulum of the sebaceous unit, - regular excretion at the surface of the skin and on the hair (100 to 500 μg / cm 2 ); it is a real reservoir. The sebum is composed of squalene (15%), waxes (25%) and triglycerides (60%) with completely specific fatty acid chains, genetically determined in their proportions for each individual. The originality of the sebaceous gland in lipid synthesis should therefore be emphasized. Sebum, because of its composition, can be considered as an oil in the physicochemical sense, which indicates a notable influence of the temperature on its flow. The role of sebum is becoming better known. It is involved in the organization of lipids within the stratum corneum and therefore participates in the barrier effect. Waxes reinforce the impermeability of the skin surface. Squalenes participate in UV protection like certain cyto ines which are spilled on its surface. Finally, the specific lipids of sebum, thanks to the action of an endogenous β-desaturase play a role in the modulation of inflammation. In addition, specific regulation of neuropeptides
(neuroendopeptidases) et une réponse sélective à certaines hormones, dont les rétinoïdes, ont également lieu dans le sébum. On notera aussi que le sébum constitue la seule voie d'excrétion de la vitamine E, que, par son apport de glycerol, il participe à l'hydratation cutanée et, en dernier lieu, qu'il participe à la régulation de l'écosystème (activité anti gram + des isomères de l'acide palmitoléique) . La position anatomique de l'unité pilosébacée place le réservoir folliculaire au croisement de deux mondes : l'un
interne et vivant, l'autre comme un environnement porteur de germes et d'oxygène. Ceci explique la transformation constante du sébum excrété à partir de sa zone de stockage, nommée par la suite réservoir folliculaire. Par ailleurs, cette position en fait également un moyen d'excrétion privilégié de certaines molécules exogènes ou endogènes et une source de cytokines IL 1 alpha ou de neuro- peptides . En dernier lieu, la glande sébacée joue un rôle important dans 1 'homeostasie cutaneophanerienne et dans le système immunitaire. En résumé, la glande sébacée présente simultanément des propriétés de sécrétion et de synthèse, de stockage et enfin d' excrétion. De nombreuses compositions cosmétiques et dermatologiques à usage topique ont été proposées dans la technique pour assurer les soins de la peau dans diverses indications, et par exemple la demande WO 0176538 décrit une composition pour la protection des lèvres comprenant un mélange de lipides choisis parmi des céramides, des acides gras essentiels et des acides gras non essentiels. Le brevet GB 2004741 concerne une composition pour le traitement de l'alopécie, à base de cholestérol, d'acides gras et d'un phospho-aminolipide. Le brevet FR 2795960 se fonde sur l'observation que certains acide gras peuvent avoir un effet relaxant sur l'organisme, et il décrit une micro-émulsion stable à base d'acides gras à groupe acide carboxylique libre pouvant être administrée par voie orale, injectable, topique, etc, pour le traitement des anxiétés. Une autre émulsion à base d'acides gras est décrite dans le brevet US 6361806, mais cette formulation est destinée à traverser l'épiderme. Le brevet DE 4113346 décrit une composition aqueuse capillaire à base de phospholipides, d'huiles et d'alcools. Toutefois, aucune des compositions décrites dans la technique n'est adaptée à l'utilisation des propriétés des glandes sébacées.
Les traitements cosmétologiques ou dermatologiques sont souvent très contraignants et peuvent alors entraîner un phénomène de lassitude chez le patient lorsque les améliorations souhaitées sont jugées trop lentes à se manifester. II existe par conséquent un besoin accru dans le domaine cosmétologique et dermatologique de trouver des méthodes d'administration alternatives, permettant une bonne observance de la part des patients. Les études effectuées par la demanderesse ont montré qu'il est possible d'utiliser la capacité de stockage que constitue la glande sébacée, et plus particulièrement le réservoir folliculaire, pour libérer de façon prolongée des principes actifs lipophiles. Ainsi, grâce à l'excrétion continue de son contenu à la surface de la peau, il a été constaté qu'il est possible d'agir, par un relargage progressif de l'actif ainsi obtenu, sur une grande variété de troubles cutanés. Pour parvenir à des formulations adaptées, la demanderesse a démontré que le véhicule devait être compatible avec le sébum humain, ne présenter aucun risque de modifier ses propriétés physicochimiques, et être choisi de manière à être préférentiellement absorbé au niveau de la glande sébacée.(neuroendopeptidases) and a selective response to certain hormones, including retinoids, also occur in the sebum. It should also be noted that sebum constitutes the only route of excretion of vitamin E, that, by its supply of glycerol, it participates in skin hydration and, lastly, that it participates in the regulation of the ecosystem. (anti gram + activity of palmitoleic acid isomers). The anatomical position of the pilosebaceous unit places the follicular reservoir at the crossroads of two worlds: one internal and living, the other as an environment carrying germs and oxygen. This explains the constant transformation of the sebum excreted from its storage area, subsequently called the follicular reservoir. Furthermore, this position also makes it a privileged means of excretion of certain exogenous or endogenous molecules and a source of IL 1 alpha cytokines or neuropeptides. Finally, the sebaceous gland plays an important role in cutaneous-canopy homeostasis and in the immune system. In summary, the sebaceous gland simultaneously exhibits secretion and synthesis, storage and finally excretion properties. Numerous cosmetic and dermatological compositions for topical use have been proposed in the art for ensuring skin care in various indications, and for example application WO 0176538 describes a composition for protecting the lips comprising a mixture of lipids chosen from ceramides. , essential fatty acids and non-essential fatty acids. Patent GB 2004 741 relates to a composition for the treatment of alopecia, based on cholesterol, fatty acids and a phospho-aminolipid. The patent FR 2795960 is based on the observation that certain fatty acids can have a relaxing effect on the body, and it describes a stable microemulsion based on fatty acids with free carboxylic acid group which can be administered orally, injectable, topical, etc., for the treatment of anxiety. Another emulsion based on fatty acids is described in US Pat. No. 6,361,806, but this formulation is intended to cross the epidermis. Patent DE 4113346 describes an aqueous hair composition based on phospholipids, oils and alcohols. However, none of the compositions described in the art is suitable for using the properties of the sebaceous glands. Cosmetological or dermatological treatments are often very restrictive and can then lead to a phenomenon of weariness in the patient when the desired improvements are considered too slow to appear. There is therefore an increased need in the cosmetic and dermatological field to find alternative methods of administration, allowing good compliance on the part of the patients. The studies carried out by the applicant have shown that it is possible to use the storage capacity that constitutes the sebaceous gland, and more particularly the follicular reservoir, to release lipophilic active ingredients for a prolonged period. Thus, thanks to the continuous excretion of its content on the surface of the skin, it has been found that it is possible to act, by a gradual release of the active ingredient thus obtained, on a wide variety of skin disorders. To arrive at suitable formulations, the applicant has demonstrated that the vehicle must be compatible with human sebum, present no risk of modifying its physicochemical properties, and be chosen so as to be preferentially absorbed at the level of the sebaceous gland.
La présente invention L' invention est donc relative à une formulation pour l'application topique localisée, comprenant une emulsion ou solution saturée contenant un ou plusieurs principes actifs lipophiles, de préférence lipidiques, dans un mélange de solvants comprenant un ou plusieurs acides gras insaturés en C4-C26 et un véhicule liquide polaire, à tropisme sébacé. Le véhicule liquide comprend préférentiellement un solvant organique polaire.
La formulation La présence d'un acide gras insaturé en C4-C26 permet à la fois d'assurer une meilleure vectorisation du principe actif du fait de sa compatibilité avec les lipides du sébum et de faciliter le relargage de ce dernier lors de la phase d'excrétion. L'acide gras insaturé en C4-C26 peut comporter de 1 à 6 insaturations, et de préférence de 1 à 6 doubles liaisons. Il peut par exemple être choisi parmi l'acide butyrique, l'acide caproïque, l'acide caprylique, l'acide caprique, l'acide laurique, l'acide myristique, l'acide palmitique, l'acide palmitoléique, l'acide stéarique, l'acide oléique, l'acide sapienique, l'acide ricinoléique, l'acide α- et γ-linoléique, l'acide α- et γ-linolénique, l'acide stéraidonique, l'acide arachidique et l'acide béhénique. Ces acides gras peuvent être utilisés isolément ou en mélange entre eux. L'acide sapienique est contenu naturellement en abondance dans la glande sébacée chez l'homme. C'est un acide gras mono- insaturé comportant 16 atomes de carbone et une unique double liaison cis au 6ème carbone à partir de la terminaison carboxyle. L'acide gras et le principe actif sont préférentiellement dissous dans un solvant organique pour assurer une absorption préférentielle au niveau de la glande sébacée. A titre d'acide gras préféré, on peut citer l'acide sapienique, l'acide linolénique et l'acide linoleique. L'acide linoleique, plus précisément l'acide α- ou γ-linoléique, est préféré. La présente invention concerne une formulation à tropisme sébacé qui peut avantageusement se présenter sous forme d'une solution simple, de préférence anhydre, ou d'une emulsion simple ou d'une emulsion de type quaternaire, saturées en principe actif. Lorsqu'il est sous forme d'une solution huileuse simple anhydre, saturée en principe actif, le véhicule est
essentiellement composé de l'acide gras et d'un solvant organique polaire. Lorsqu'il est sous forme d'une emulsion de type quaternaire, typiquement d'une microémulsion, saturée en principe actif, le véhicule liquide polaire est un système quaternaire comportant une phase hydrophile, une phase huileuse, un agent tensioactif et un cotensioactif . Une telle microémulsion est liquide, translucide, et isotrope. Dans les deux cas, la formulation contient option- nellement un inhibiteur de cristallisation et/ou un antioxydant et/ou tout autre excipient compatible avec le mode d'administration utilisé selon la présente invention ainsi que cela est détaillé ci-après. Une « formulation pour l'application topique localisée » est également couramment dénommée formulation de type « Spot-on »; les deux terminologies peuvent être utilisés indifféremment dans le cadre de la présente invention ; elles signifient qu'elles sont destinées à traiter, par le biais d'une application ciblée du principe actif, des zones cutanées précises, sujettes à une affection particulière de la peau. Ce type de formulation, bien connu dans le domaine de la médecine vétérinaire, se caractérise par le fait que l'application d'une dose unique, typiquement d'une seule goutte, sans étalement, de ladite formulation sur la peau permet, grâce à un phénomène de dispersion, d'atteindre une grande quantité de glandes sébacées de la zone affectée. Ainsi, une formulation spot-on contenant une association de 1-N-phénylpyrazoles et de lactones macrocycliques endectocides, utile pour lutter contre les parasites dans le domaine de la médecine vétérinaire est décrite dans le brevet US 6.426.333. Après application d'une formulation de type spot-on selon la présente invention, le principe actif est stocké dans les glandes sébacées, et plus particulièrement au niveau du réservoir folliculaire, puis relargué progressivement dans le flux sébacé sur le stratum corneum, selon le rythme
physiologique d'excrétion des glandes sébacées. Plus précisément, la formulation selon la présente invention présente notamment l'avantage de permettre une incorporation aisée du principe actif lipophile dans le réservoir folliculaire de l'unité pilosébacée puis de permettre non seulement une répartition régulière du principe actif sur la peau mais encore une libération étalée dans le temps du principe actif. De cette façon, le principe actif pourra alors exercer une action ciblée sur la peau au niveau du stratum corneum. Les formulations selon la présente invention ne visent pas le passage de la barrière cutanée. Autrement dit, le passage dans le sang est très limité. Bien entendu, les objectifs de traitement cosmétique et/ou dermatologique varient en fonction du principe actif utilisé . Ainsi, grâce aux formulations selon la présente invention, on peut traiter de façon distincte ou simultanée les affections de la peau directement liées à des dysrégu- lations des glandes sébacées elles-mêmes ou bien encore toute autre affection de la peau, pour autant qu' il existe un principe actif lipophile pour la traiter. On comprend bien dans ce dernier cas que l'on utilise exclusivement les glandes sébacées comme réservoir de stockage pour une libération lente du principe actif au niveau du stratum corneum. C'est le cas par exemple lorsque le principe actif est un céramide ou un de ses précurseurs, comme indiqué ci-dessous. Ainsi, parmi les affections liées à une dysrégulation des glandes sébacées, on trouve les déficits ou les excès de la sécrétion sébacée. Le déficit de la sécrétion sébacée peut provenir du vieillissement de la peau et résulter de conditions d'atrophies localisées ; l'excès, c'est-à-dire la séborrhée, peut être source d'acné ou de dermites inflammatoires telles les dermites séborrhéiques.
Les principes actifs adaptés à la formulation Tout principe actif présentant des propriétés lipophiles peut être utilisé, et de préférence un principe actif lipidique. On peut en particulier citer les principes actifs lipophiles suivants, adaptés pour la formulation selon la présente invention : toute vitamine liposoluble, telle que la vitamine A et ses dérivés, la vitamine E et ses dérivés ; tout agent antiradicalaire lipophile ; les céramides ou leurs précurseurs de type bases sphingoïdes telles que la sphingo- sine ou la phytosphingosine ; les hormones stéroïdiennes, telles que les œstrogènes ou la progestérone et les acides gras essentiels, tels que l'acide linoleique et l'acide linolénique . Les natures et rôles des différents principes actifs listés ci-dessus sont décrits ci-après : La vitamine A, également connue sous le nom de rétinol, est une substance extrêmement utilisée en cosmétologie notamment en raison de sa fonction physiologique majeure, particulièrement dans le règlement de la prolifération et de la differentiation d'un certain nombre de types de cellules. Il est notamment connu que l'application topique du rétinol stabilise l'équilibre de vitamine A dans la peau et que cet équilibre peut être altéré en particulier par l'exposition à la lumière UV. Ainsi, l'insuffisance en vitamine A mène en particulier à une augmentation de la formation des rides, spécialement en cas de surexposition au soleil ("photovieillissement") . L'insuffisance de la vitamine A mène également à une perte de l'élasticité de la peau et affaiblit la fonction de barrière de la peau contre des micro- organismes. Enfin, le rétinol est couramment employé dans le traitement de l'acné. Avantageusement, on peut utiliser la vitamine A sous sa forme naturelle (rétinol) ou sous forme de son acide (acide rétinoïque) ou encore d'acétate de rétinyle, de rétinaldéhyde, de β-carotène ou de palmitate de rétinyle, dans le cadre de la présente invention.
La vitamine E et ses dérivés sont des substances qui, en vertu de leurs propriétés présumées comme agent antiradicalaire (suppresseurs des radicaux libres), sont largement répandues en cosmétologie et en dermatologie. La vitamine E, également nommée tocopherol, peut avantageusement être incorporée à la formulation selon la présente invention pure (forme naturelle) ou sous forme d'ester et en particulier sous forme d'acétate de tocopherol, de linoléate de tocopherol ou de succinate de tocopherol. A titre d'agent antiradicalaire lipophile on peut également citer les dérivés de l'acide -lipoïque, les andro- grapholides, les dérivés lipophiles de la vitamine C tels que des esters, par exemple le palmitate et le stéarate d'ascor- byle. La phytosphingosine et la sphingosine, précurseurs de céramides, présents dans la peau humaine, ont des propriétés inhibitrices de la protéine kinase C. Ces molécules semblent par ailleurs impliquées dans la différenciation des kérati- nocytes de l'épiderme. On a également observé que des sphingo- sines présentes dans le stratum corneum et d'autres couches de l'épiderme, inhibent la croissance de certains micro-organismes indésirables. Elles trouvent ainsi notamment leur application dans le traitement de l'acné, de la dermite séborrhéique et de l'hyper-séborrhée. Les bases sphingoïdes utilisées dans les formulations de la présente invention peuvent être obtenues par des méthodes connues à partir de diverses sources appropriées, par exemple à partir de sources naturelles ou par synthèse chimique ou par fermentation. Les procédés de synthèse chimique sont généra- lement relativement coûteux et ne permettent pas toujours d'obtenir les bases sphingoïdes ayant les configurations stéréochimiques voulues. Les bases sphingoïdes peuvent aussi être obtenues à partir de tissus animaux ou végétaux par extraction et purification, mais ces méthodes sont généra-
lement coûteuses et les sources animales ne présentent pas toujours les qualités bactériologiques voulues. C'est pourquoi les bases sphingoïdes utilisées dans l'invention sont de préférence préparées par fermentation microbienne, par exemple à partir d'une levure telle que Pichia ciferii, et la phytosphingosine obtenue de la sorte présente l'avantage d'être très proche de celle de la peau de l'animal. Suivant une forme préférentielle de réalisation de l'invention, on utilise comme base sphingoïde la phytosphin- gosine obtenue à partir de tétra-acétyl-phytosphingosine (TAPS) dérivée de Pichia ciferii par désacétylation. La réaction de désacétylation peut s'effectuer par réaction chimique, par exemple par hydrolyse en présence de potasse, ou par réaction enzymatique. Pour obtenir une phytosphingosine de haute pureté, il est préférable de procéder à une purification en sortie d'hydrolyse. Tout procédé de purification connu dans la technique peut convenir. Dans le cadre de la présente invention la base sphingoïde est avantageusement choisie parmi la sphingosine, la sphinganine, la phytosphingosine, la tétracétylphytosphingosine, la N-acétylphytosphingosine, le chlorhydrate de phytosphingosine et le salicylate de phytosphingosine. Les hormones stéroïdiennes telles que les œstrogènes, les anti-androgènes ou la progestérone sont connues pour leur capacité à lutter contre certaines formes de séborrhée, la maladie de Fox et Fordyce, l'alopécie androgénique, l'acné et 1' hirsutisme.The present invention The invention therefore relates to a formulation for localized topical application, comprising an emulsion or saturated solution containing one or more lipophilic active principles, preferably lipidic, in a mixture of solvents comprising one or more unsaturated fatty acids in C 4 -C 26 and a polar liquid vehicle, with sebaceous tropism. The liquid vehicle preferably comprises a polar organic solvent. The formulation The presence of an unsaturated C 4 -C 26 fatty acid makes it possible both to ensure better vectorization of the active principle due to its compatibility with the lipids of the sebum and to facilitate the release of the latter during the excretion phase. The unsaturated C 4 -C 26 fatty acid may contain from 1 to 6 unsaturations, and preferably from 1 to 6 double bonds. It can for example be chosen from butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, acid stearic, oleic acid, sapienic acid, ricinoleic acid, α- and γ-linoleic acid, α- and γ-linolenic acid, steraidonic acid, arachidic acid and acid behenic. These fatty acids can be used individually or as a mixture between them. Sapienic acid is naturally found in abundance in the sebaceous gland in humans. It is a monounsaturated fatty acid having 16 carbon atoms and a single cis double bond at the 6th carbon from the carboxyl terminus. The fatty acid and the active principle are preferably dissolved in an organic solvent to ensure preferential absorption in the sebaceous gland. Mention may be made, as preferred fatty acid, of sapienic acid, linolenic acid and linoleic acid. Linoleic acid, more precisely α- or γ-linoleic acid, is preferred. The present invention relates to a sebaceous tropism formulation which can advantageously be in the form of a simple solution, preferably anhydrous, or of a simple emulsion or of an emulsion of quaternary type, saturated with active principle. When it is in the form of a simple anhydrous oily solution, saturated with active principle, the vehicle is essentially composed of fatty acid and a polar organic solvent. When it is in the form of a quaternary type emulsion, typically a microemulsion, saturated with active principle, the polar liquid vehicle is a quaternary system comprising a hydrophilic phase, an oily phase, a surfactant and a cosurfactant. Such a microemulsion is liquid, translucent, and isotropic. In both cases, the formulation optionally contains a crystallization inhibitor and / or an antioxidant and / or any other excipient compatible with the mode of administration used according to the present invention, as detailed below. A “formulation for localized topical application” is also commonly called a “Spot-on” type formulation; the two terminologies can be used interchangeably in the context of the present invention; they mean that they are intended to treat, by means of a targeted application of the active principle, precise cutaneous zones, prone to a particular affection of the skin. This type of formulation, well known in the field of veterinary medicine, is characterized by the fact that the application of a single dose, typically of a single drop, without spreading, of said formulation to the skin allows, thanks to a phenomenon of dispersal, reaching a large amount of sebaceous glands from the affected area. Thus, a spot-on formulation containing a combination of 1-N-phenylpyrazoles and endectocidal macrocyclic lactones, useful for combating parasites in the field of veterinary medicine is described in US Pat. No. 6,426,333. After application of a spot-on type formulation according to the present invention, the active principle is stored in the sebaceous glands, and more particularly in the follicular reservoir, then gradually released into the sebaceous flow on the stratum corneum, according to the rhythm physiological excretion of the sebaceous glands. More specifically, the formulation according to the present invention has in particular the advantage of allowing easy incorporation of the lipophilic active principle into the follicular reservoir of the pilosebaceous unit and then of allowing not only a regular distribution of the active principle on the skin but also a release. spread over time of the active ingredient. In this way, the active ingredient can then exert a targeted action on the skin at the level of the stratum corneum. The formulations according to the present invention do not target the passage of the skin barrier. In other words, the passage through the blood is very limited. Of course, the cosmetic and / or dermatological treatment objectives vary depending on the active ingredient used. Thus, thanks to the formulations according to the present invention, it is possible to treat, separately or simultaneously, the skin conditions directly linked to dysregulations of the sebaceous glands themselves or even any other skin condition, provided that there is a lipophilic active ingredient to treat it. It is clearly understood in the latter case that the sebaceous glands are used exclusively as a storage reservoir for a slow release of the active principle at the level of the stratum corneum. This is the case, for example, when the active principle is a ceramide or one of its precursors, as indicated below. Thus, among the conditions linked to a dysregulation of the sebaceous glands, we find deficits or excess of sebaceous secretion. The deficit in sebaceous secretion can come from aging of the skin and result from localized atrophy conditions; excess, that is to say seborrhea, can be a source of acne or inflammatory dermatitis such as seborrheic dermatitis. The active ingredients suitable for the formulation Any active ingredient having lipophilic properties can be used, and preferably a lipid active ingredient. Mention may in particular be made of the following lipophilic active principles, suitable for the formulation according to the present invention: any fat-soluble vitamin, such as vitamin A and its derivatives, vitamin E and its derivatives; any lipophilic anti-radical agent; ceramides or their sphingoid base type precursors such as sphingosine or phytosphingosine; steroid hormones, such as estrogen or progesterone, and essential fatty acids, such as linoleic acid and linolenic acid. The natures and roles of the various active ingredients listed above are described below: Vitamin A, also known under the name of retinol, is a substance extremely used in cosmetology in particular because of its major physiological function, particularly in the regulation proliferation and differentiation of a number of cell types. It is known in particular that the topical application of retinol stabilizes the balance of vitamin A in the skin and that this balance can be altered in particular by exposure to UV light. Thus, vitamin A deficiency leads in particular to an increase in the formation of wrinkles, especially in the event of overexposure to the sun ("photoaging"). Insufficient vitamin A also leads to a loss of skin elasticity and weakens the barrier function of the skin against microorganisms. Finally, retinol is commonly used in the treatment of acne. Advantageously, vitamin A can be used in its natural form (retinol) or in the form of its acid (retinoic acid) or alternatively retinyl acetate, retinaldehyde, β-carotene or retinyl palmitate, in the context of the present invention. Vitamin E and its derivatives are substances which, by virtue of their presumed properties as anti-free radicals (free radical suppressants), are widely used in cosmetology and dermatology. Vitamin E, also called tocopherol, can advantageously be incorporated into the formulation according to the present invention pure (natural form) or in the form of an ester and in particular in the form of tocopherol acetate, tocopherol linoleate or tocopherol succinate . Mention may also be made, as lipophilic anti-radical agent, of lipoic acid derivatives, andrographolides, of lipophilic vitamin C derivatives such as esters, for example palmitate and ascorbyl stearate. Phytosphingosine and sphingosine, precursors of ceramides, present in human skin, have inhibitory properties of protein kinase C. These molecules also seem to be involved in the differentiation of keratinocytes of the epidermis. It has also been observed that sphingosines present in the stratum corneum and other layers of the epidermis inhibit the growth of certain undesirable microorganisms. They thus find their application in particular in the treatment of acne, seborrheic dermatitis and hyper-seborrhea. The sphingoid bases used in the formulations of the present invention can be obtained by known methods from various suitable sources, for example from natural sources or by chemical synthesis or by fermentation. Chemical synthesis methods are generally relatively expensive and do not always make it possible to obtain the sphingoid bases having the desired stereochemical configurations. The sphingoid bases can also be obtained from animal or plant tissues by extraction and purification, but these methods are generally Lely expensive and animal sources do not always have the desired bacteriological qualities. This is why the sphingoid bases used in the invention are preferably prepared by microbial fermentation, for example from a yeast such as Pichia ciferii, and the phytosphingosine obtained in this way has the advantage of being very close to that of the animal's skin. According to a preferred embodiment of the invention, as the sphingoid base, the phytosphigosine obtained from tetra-acetyl-phytosphingosine (TAPS) derived from Pichia ciferii by deacetylation is used. The deacetylation reaction can be carried out by chemical reaction, for example by hydrolysis in the presence of potassium hydroxide, or by enzymatic reaction. To obtain a high purity phytosphingosine, it is preferable to carry out a purification at the outlet of hydrolysis. Any purification method known in the art may be suitable. In the context of the present invention, the sphingoid base is advantageously chosen from sphingosine, sphinganine, phytosphingosine, tetracetylphytosphingosine, N-acetylphytosphingosine, phytosphingosine hydrochloride and phytosphingosine salicylate. Steroid hormones such as estrogens, antiandrogens or progesterone are known for their ability to combat certain forms of seborrhea, Fox and Fordyce disease, androgenic alopecia, acne and hirsutism.
Les composants de la formulation La formulation peut se présenter soit sous forme d'une solution huileuse simple , soit sous forme d'une emulsion simple ou quaternaire, la formulation étant dans les deux cas saturée en principe actif lipidique. Elle comprend, outre l'acide gras, un solvant organique polaire qui peut être tout solvant organique polaire généralement acceptable dans une
formulation pour une application topique, connu de l'homme de l'art. Comme solvants organiques polaires on peut utiliser en particulier l'acétone, l'acétate d'éthyle, le méthanol, l'éthanol, 1 ' isopropanol, le diméthylformamide, le diéthylène glycol, le dichloromethane, le mono-éthyléther de diéthylène glycol (Transcutol) . Un solvant capable de faciliter ou d'améliorer la pénétration des principes actifs dans la peau peut aussi être avantageusement utilisé dans les compositions de l'invention, et par exemple un dérivé de glycerol amphi- phile non ionique tel que le 1, 2-O-isopropylidèneglycérol (Solketal) . Ces solvants peuvent être complétés par divers excipients selon la nature des phases désirées, tels que le triglycéride caprylique/caprate C8-C10 (Estasan ou Miglyol 812), ou l'acide oléique. Dans le cadre de la présente invention, on utilise de préférence le Transcutol et le Solketal, connus pour leur forte lipophilie non sélective. Dans le cas d'une solution simple, un cosolvant volatil peut avantageusement être associé au solvant principal, et par exemple un alcool tel que l'éthanol et le glycol, pour faciliter le séchage après application, et entraîner une sursaturation du principe actif. Dans le cas d'une emulsion simple ou quaternaire, la formulation comprend une phase huileuse et une phase hydrophile. Ce cosolvant peut être non polaire et être constitué par exemple par l'acide linoleique. Lors de l'application sur la peau, au contact de la couche cornée dans une zone comportant des glandes sébacées, la différence de coefficients de partition existant entre le véhicule sursaturé et le stratum corneum crée une diffusion du principe actif lipidique vers les lipides sébacés et son stockage dans les glandes sébacées. Le caractère anhydre de la composition de l'invention favorise sa stabilité dans le temps. Toutefois, dans le cas des émulsions une phase aqueuse peut être présente mais l'eau
ne représente pas plus de 5% en poids par rapport au poids total de la composition. La phase huileuse est formée par le principe actif lipophile solubilisé dans le ou les acide (s) gras insaturé (s) en C-C26, éventuellement complétée par des huiles minérales ou des huiles végétales, des glycérides polyglycosylés insaturés ou des triglycérides, ou encore des mélanges de tels composés. La phase hydrophile peut en particulier être formée de dérivés de glycol en général, tels que le propylène glycol, les éthers de glycol, les polyéthylène glycols ou le glycerol. Le propylène glycol, le diéthylène glycol, le mono-éthyl éther de diéthylène glycol et le mono-éthyl éther de dipropylène glycol sont particulièrement préférés. Les agents tensioactifs pour la microémulsion peuvent être choisis parmi le monoethyl éther de diéthylène glycol, le monométhyl éther de dipropylèneglycol, les glycérides Cβ-Cio polyglycolysés et le 6-dioléate de polyglycéryle . Plus particulièrement lorsque la formulation selon la présente invention se présente sous forme d'une microémulsion, elle se caractérise par une dispersion stable de micro- goutelettes de la phase huileuse dans la phase aqueuse, ou inversement de micro-goutelettes de la phase aqueuse dans la phase huileuse. La taille de ces micro-goutelettes est de moins de 200 nm (1.000 à 100.000 nm pour des émulsions) . Le film interfacial se compose d'une alternance de molécules tensioactives (TA) et Co-tensioactives (CoTa) qui, en abaissant la tension interfaciale, permettent la formation spontanée de la microémulsion. Dans la microémulsion, la phase huileuse est présente dans une teneur pouvant être comprise entre 2 et 15%, plus particulièrement entre 7 et 10%, et de préférence entre 8 et 9% par rapport au volume total de la formulation. Généralement, la phase aqueuse est présente dans une teneur pouvant être comprise entre 1 et 4% par rapport au volume total de la formulation. La microémulsion contient de préférence de 25 à
75% d'agent tensioactif et de 10 à 55% de cotensioactif par rapport au volume total de la formulation. Par ailleurs, le rapport cotensioactif sur tensioactif est de préférence compris entre 1/7 et 1/2. Ainsi les cotensioactifs peuvent être choisis parmi les alcools à chaîne courte, tels que l'éthanol et le glycol Quelques composés sont communs aux trois composants discutés ci-dessus, c.-à-d., phase hydrophile, agent tensioactif et cotensioactif. L'inhibiteur de cristallisation peut s'avérer très avantageux lorsqu'il existe un risque de cristallisation d'un principe actif. Il est alors utile pour que le principe actif atteigne le réservoir folliculaire aisément, mais encore pour que la phase de relargage soit facilitée, c'est-à-dire pour que le principe actif soit effectivement soluble dans le sébum. L'inhibiteur de cristallisation peut en particulier être présent dans une teneur de 1 à 20% en poids par rapport au volume total de la formulation, de préférence de 5 à 15%. Les inhibiteurs de cristallisation qui peuvent être employés dans l'invention incluent : - la polyvinylpyrrolidone (PVP), les alcools poly- vinyliques, les copolymères d'acétate de vinyle et de vinyl- pyrrolidone, les polyéthylène glycols, l'alcool benzylique, le mannitol, le glycerol, le sorbitol, les esters de sorbitane polyoxyéthylénés ; la lécithine, la carboxyméthyl cellulose sodique ; les dérivés acryliques tels que les méthacrylates et d'autres ; - les tensioactifs anioniques, tels que les stéarates alcalins, en particulier le stéarate de sodium, le stéarate de potassium ou le stéarate d'ammonium ; le stéarate de calcium, le stéarate de triéthanolamine ; l'abiétate de sodium ; les sulfates d'alkyle, en particulier le laurylsulfate de sodium et le cétylsulfate de sodium ; le dodécylbenzenesulfonate de
sodium, le dioctylsulfosuccinate de sodium ; les acides gras, en particulier ceux dérivés de l'huile de coprah ; - les tensioactifs cationiques, tels que les sels hydrosolubles d'ammonium quaternaire représentés par la formule N+RιR2R3R, Y" dans laquelle les radicaux Ri à R4, identiques ou différents, sont des radicaux hydrocarbonés, éventuellement hydroxylés, et Y" est un anion d'un acide fort, tel que des anions d' halogénure, sulfate et sulfonate ; le bromure de cétyl triméthyl ammonium est l'un des tensioactifs cationiques qui peuvent être employés ; - les sels d'aminé de formule N+R' R' ' R' ' ' dans laquelle les radicaux R, identiques ou différents, sont des radicaux hydrocarbonés, éventuellement hydroxylés ; le chlorhydrate d' octadécylamine est l'un des tensioactifs cationiques qui peuvent être employés ; - les agents tensioactifs non ioniques tels que les esters de sorbitane, éventuellement polyoxyéthylénés, en particulier le Polysorbate 80, les éthers d'alkyle polyoxy- éthyléné ; le stéarate de polyéthylène glycol, les dérivés polyoxyethylenates de l'huile de ricin, les esters de poly- glycérol, les alcools gras polyoxyethylenates, les acides gras polyoxyethylenates, les copolymères d'oxyde d' éthylène et d' oxyde de propylène ; - les tensioactifs amphotères tels que les composés lauryle substitués de la bétaïne ; - ou de préférence un mélange d' au moins deux des composés énumérés ci-dessus. La formulation peut également comporter un antioxydant prévu pour éviter toute lipoperoxydation, cet agent étant en particulier présent dans une teneur comprise entre 0,005 à 1% (P/V), de préférence entre 0,01 à 0,05%. On peut utiliser tout antioxydant conventionnel pour l'homme de l'art. On peut notamment citer le butylhydroxy- anisole (BHA) , le butylhydroxytoluène (BHT) , l'acide ascor- bique, le métabisulfite de sodium, le gallate de propyle, le
thiosulfate de sodium ou un mélange d'au plus deux d'entre eux. Les composants décrits ci-dessus, utiles pour préparer le véhicule liquide de la formulation selon la présente invention, sont bien connus de l'homme de l'art et peuvent être obtenus commercialement ou par des techniques connues. Les formulations selon la présente invention sont généralement préparées par le simple mélange des composants décrits ci-dessus ; avantageusement, on commence par mélanger le principe actif dans le solvant organique, et on ajoute ensuite les autres composants.The components of the formulation The formulation can be presented either in the form of a simple oily solution, or in the form of a simple or quaternary emulsion, the formulation being in both cases saturated with lipid active principle. It comprises, in addition to the fatty acid, a polar organic solvent which can be any polar organic solvent generally acceptable in a formulation for topical application, known to those skilled in the art. As polar organic solvents, acetone, ethyl acetate, methanol, ethanol, isopropanol, dimethylformamide, diethylene glycol, dichloromethane, monoethyl ether of diethylene glycol (Transcutol) can be used in particular. ). A solvent capable of facilitating or improving the penetration of the active ingredients into the skin can also be advantageously used in the compositions of the invention, and for example a non-ionic amphiphilic glycerol derivative such as 1, 2-O -isopropylidene glycerol (Solketal). These solvents can be supplemented with various excipients depending on the nature of the phases desired, such as the caprylic triglyceride / C8-C10 caprate (Estasan or Miglyol 812), or oleic acid. In the context of the present invention, use is preferably made of Transcutol and Solketal, known for their high non-selective lipophilicity. In the case of a simple solution, a volatile cosolvent can advantageously be associated with the main solvent, and for example an alcohol such as ethanol and glycol, to facilitate drying after application, and cause oversaturation of the active principle. In the case of a simple or quaternary emulsion, the formulation comprises an oily phase and a hydrophilic phase. This cosolvent can be non-polar and be constituted for example by linoleic acid. When applied to the skin, in contact with the stratum corneum in an area comprising sebaceous glands, the difference in partition coefficients existing between the supersaturated vehicle and the stratum corneum creates a diffusion of the lipid active principle towards the sebaceous lipids and its storage in the sebaceous glands. The anhydrous nature of the composition of the invention promotes its stability over time. However, in the case of emulsions an aqueous phase may be present but the water does not represent more than 5% by weight relative to the total weight of the composition. The oily phase is formed by the lipophilic active principle dissolved in the unsaturated fatty acid (s) in CC 26 , optionally supplemented with mineral oils or vegetable oils, unsaturated polyglycosylated glycerides or triglycerides, or alternatively mixtures of such compounds. The hydrophilic phase can in particular be formed from glycol derivatives in general, such as propylene glycol, glycol ethers, polyethylene glycols or glycerol. Propylene glycol, diethylene glycol, monoethyl ether of diethylene glycol and monoethyl ether of dipropylene glycol are particularly preferred. The surface-active agents for the microemulsion can be chosen from monoethyl ether of diethylene glycol, monomethyl ether of dipropylene glycol, polyglycolysed Cβ-Cio glycerides and polyglyceryl 6-dioleate. More particularly when the formulation according to the present invention is in the form of a microemulsion, it is characterized by a stable dispersion of micro-droplets of the oily phase in the aqueous phase, or conversely of micro-droplets of the aqueous phase in the oily phase. The size of these micro-droplets is less than 200 nm (1,000 to 100,000 nm for emulsions). The interfacial film consists of an alternation of surfactant molecules (TA) and Co-surfactants (CoTa) which, by lowering the interfacial tension, allow the spontaneous formation of the microemulsion. In the microemulsion, the oily phase is present in a content which can be between 2 and 15%, more particularly between 7 and 10%, and preferably between 8 and 9% relative to the total volume of the formulation. Generally, the aqueous phase is present in a content which can be between 1 and 4% relative to the total volume of the formulation. The microemulsion preferably contains from 25 to 75% surfactant and 10 to 55% cosurfactant relative to the total volume of the formulation. Furthermore, the cosurfactant to surfactant ratio is preferably between 1/7 and 1/2. Thus the cosurfactants can be chosen from short-chain alcohols, such as ethanol and glycol. Some compounds are common to the three components discussed above, ie, hydrophilic phase, surfactant and cosurfactant. The crystallization inhibitor can prove to be very advantageous when there is a risk of crystallization of an active principle. It is then useful so that the active principle reaches the follicular reservoir easily, but also so that the release phase is facilitated, that is to say so that the active principle is effectively soluble in the sebum. The crystallization inhibitor can in particular be present in a content of 1 to 20% by weight relative to the total volume of the formulation, preferably from 5 to 15%. The crystallization inhibitors which can be used in the invention include: - polyvinylpyrrolidone (PVP), polyvinyl alcohols, copolymers of vinyl acetate and of vinyl pyrrolidone, polyethylene glycols, benzyl alcohol, mannitol, glycerol, sorbitol, polyoxyethylene sorbitan esters; lecithin, sodium carboxymethyl cellulose; acrylic derivatives such as methacrylates and others; - anionic surfactants, such as alkali stearates, in particular sodium stearate, potassium stearate or ammonium stearate; calcium stearate, triethanolamine stearate; sodium abietate; alkyl sulfates, in particular sodium lauryl sulfate and sodium cetyl sulfate; dodecylbenzenesulfonate sodium, sodium dioctylsulfosuccinate; fatty acids, in particular those derived from coconut oil; cationic surfactants, such as the water-soluble quaternary ammonium salts represented by the formula N + RιR 2 R 3 R, Y " in which the radicals Ri to R 4 , identical or different, are hydrocarbon radicals, optionally hydroxylated, and Y " is an anion of a strong acid, such as halide, sulfate and sulfonate anions; cetyl trimethyl ammonium bromide is one of the cationic surfactants which can be used; - the amine salts of formula N + R 'R''R''' in which the radicals R, identical or different, are hydrocarbon radicals, optionally hydroxylated; octadecylamine hydrochloride is one of the cationic surfactants which can be used; - nonionic surfactants such as sorbitan esters, optionally polyoxyethylenated, in particular Polysorbate 80, polyoxyethylenated alkyl ethers; polyethylene glycol stearate, polyoxyethylenate derivatives of castor oil, polyglycerol esters, polyoxyethylenate fatty alcohols, polyoxyethylenate fatty acids, copolymers of ethylene oxide and propylene oxide; - amphoteric surfactants such as substituted lauryl compounds of betaine; - Or preferably a mixture of at least two of the compounds listed above. The formulation may also include an antioxidant intended to avoid any lipoperoxidation, this agent being in particular present in a content of between 0.005 to 1% (W / V), preferably between 0.01 to 0.05%. Any conventional antioxidant can be used for those skilled in the art. Mention may in particular be made of butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), ascorbic acid, sodium metabisulfite, propyl gallate, sodium thiosulfate or a mixture of not more than two of them. The components described above, useful for preparing the liquid vehicle of the formulation according to the present invention, are well known to those skilled in the art and can be obtained commercially or by known techniques. The formulations according to the present invention are generally prepared by the simple mixing of the components described above; advantageously, one begins by mixing the active principle in the organic solvent, and then the other components are added.
L'application de la formulation Les formulations selon l'invention sont extrêmement efficaces pour de longues durées de temps dans les différents traitements décrits plus haut. Les formulations selon la présente invention peuvent être conditionnées dans des flacons avec des applicateurs adaptés. Typiquement la formulation peut être appliquée sous forme d'une ou de plusieurs gouttes à répartir sur les zones à traiter. La posologie est adaptée en fonction de l'actif utilisé et de l'affection à traiter. Par exemple, elle peut être comprise entre 10 et 25 gouttes appliquées sur le visage, dans le cas de l'acide rétinoïque en solution à 0,5%. On peut également noter que le flux de la phase d'excrétion du sébum dépend de la température. Ce paramètre peut être utilisé avantageusement lorsqu'on cherche à administrer un agent antiradicalaire lipophile. En effet, la température ayant un effet fluidifiant sur le sébum, l'agent antiradicalaire pourra être libéré plus rapidement lorsque la peau sera exposée au soleil.
L'utilisation de la formulation L' invention concerne une méthode de traitement cosmétique de la peau destinée au traitement ou à la prévention de dommages de la peau associés au vieillissement de la peau pouvant consister en une perte de la fermeté de la peau, de la tonicité de la peau et l'apparition de ridules et rides, consistant à appliquer sur les zones affectées de la peau une formulation selon la présente invention contenant de la vitamine A, par exemple sous forme d'acétate de rétinyle, de palmitate de rétinyle, d'acide rétinoïque, de rétinaldéhyde ou de β-carotène. L' invention concerne aussi une méthode de traitement cosmétique de la peau destinée au traitement ou à la prévention de dommages de la peau associés au photovieil- lissement de la peau, consistant à appliquer sur les zones affectées de la peau une formulation selon la présente invention contenant de la vitamine A, par exemple sous forme d'acétate de rétinyle, de palmitate de rétinyle, d'acide rétinoïque, de rétinaldéhyde ou de β-carotène, de la vitamine E, par exemple sous forme d'acétate de tocopherol ou de succinate de tocopherol, ou encore tout agent antiradicalaire lipophile, par exemple sous forme d'acide -lipoïque, d'andro- grapholides, d'esters de la vitamine C comme le palmitate et le stéarate d'ascorbyle. De plus, l'invention concerne une méthode de traitement cosmétique de la peau destinée au gommage ou peeling de celle- ci, consistant à appliquer sur la peau une formulation selon la présente invention contenant de l'acide rétinoïque concentré, de préférence entre 0,1 et 1%. En outre, l'invention concerne une formulation de type spot-on selon la présente invention pour son utilisation à titre de composition dermatologique pour la médecine humaine. Plus particulièrement l'invention est relative à : - une formulation de type spot-on selon la présente invention, comprenant de la vitamine A, une hormone stéroï-
dienne, un ceramide ou l'un de ses précurseurs de type base sphingoïde ou bien un acide gras essentiel, pour son utilisation à titre composition dermatologique destinée à traiter l'acné, - une formulation de type spot-on selon la présente invention, comprenant un ceramide ou l'un de ses précurseurs de type base sphingoïde ou bien une hormone steroïdienne, pour son utilisation à titre de composition dermatologique destinée à traiter la séborrhée, - une formulation de type spot-on selon la présente invention, comprenant un ceramide ou l'un de ses précurseurs de type base sphingoïde ou bien un acide gras essentiel, pour son utilisation à titre de composition dermatologique destinée à traiter la dermite séborrhéique, - une formulation de type spot-on selon la présente invention, comprenant de la vitamine E, de la vitamine A ou bien du glycerol, pour son utilisation à titre de composition dermatologique destinée à traiter le déficit sébacé, - une formulation de type spot-on selon la présente invention, comprenant une hormone steroïdienne à visée antiinflammatoire, pour son utilisation à titre de composition dermatologique destinée à traiter la maladie de Fox et Fordyce, ou une substance hormonale anti-androgène dans le cadre de l'alopécie androgénique et de l' hirsutisme, - une formulation de type spot-on selon la présente invention, comprenant un ceramide ou l'un de ses précurseurs de type base sphingoïde, pour son utilisation à titre de composition dermatologique destinée à traiter les folliculites chroniques du cuir chevelu, - une formulation de type spot-on selon la présente invention, comprenant un acide gras essentiel, pour son utilisation à titre de composition dermatologique destinée à traiter l'ichtyose dans sa localisation au niveau du cuir chevelu.
- une formulation de type spot-on selon la présente invention, comprenant un ester d'acide kojique, un extrait de licorice, une hormone steroïdienne, de la vitamine A ou bien un ceramide ou un de ses précurseurs de type base sphingoïde, pour son utilisation à titre de composition dermatologique destinée à traiter les lentigos actiniques, les troubles pigmentaires liés au vieillissement et l' hypermélanose. De plus, l'invention concerne l'utilisation d'un principe actif lipophile à visée cutanée pour la préparation d'une formulation pour l'application topique localisée chez l'homme, destinée à être absorbée par les glandes sébacées puis relarguées progressivement dans le temps par ces dernières sur le stra tum corneum, selon son flux sécrétoire. L'invention concerne l'utilisation d'un principe actif choisi parmi la vitamine A, par exemple sous forme pure (rétinol) ou sous forme d'acétate de rétinyle, de palmitate ou de rétinyle d'acide rétinoïque, de rétinaldéhyde ou de β- carotène ; les hormones stéroïdiennes, par exemple les œstrogènes, la progestérone et les antiandrogènes ; les céramides ou leurs précurseurs tels que les bases sphingoïdes, par exemple la sphingosine, la sphinganine, la phytosphingosine, la tétracétylphytosphingosine, la N-acétylphytosphingosine, le chlorhydrate de phytosphingosine et le salicylate de phytosphingosine; les acides gras essentiels, par exemple l'acide linoleique et l'acide linolénique, pour la préparation d'une formulation selon la présente invention, destinée à traiter 1' acné. De plus, l'invention concerne l'utilisation d'un principe actif choisi parmi les céramides ou leurs précurseurs tels que les bases sphingoïdes, par exemple la sphingosine, la sphinganine, la phytosphingosine, la tétracétylphytosphingosine, la N-acétylphytosphingosine, le chlorhydrate de phytosphingosine et le salicylate de phytosphingosine; les hormones stéroïdiennes par exemple les œstrogènes, la progestérone ou
les antiandrogènes, pour la préparation d'une formulation selon la présente invention, destinée à traiter la séborrhée. L'invention concerne encore l'utilisation d'un principe actif choisi parmi les céramides ou leurs précurseurs tels qu'une base sphingoïde par exemple la sphingosine, la sphinganine, la phytosphingosine, la tétracétylphytosphingosine, la N-acétylphytosphingosine, le chlorhydrate de phytosphingosine et le salicylate de phytosphingosine; les acides gras essentiels par exemple l'acide linoleique et l'acide linolé- nique, pour la préparation d'une formulation selon la présente invention, destinée à traiter la dermite séborrhéique. En outre, l'invention concerne l'utilisation d'un principe actif chois parmi la vitamine E, par exemple l'acétate de tocopherol, le succinate de tocopherol ; la vitamine A, par exemple l'acétate de rétinyle, le palmitate de rétinyle, l'acide rétinoïque, le rétinaldéhyde ou le β-carotène et le glycerol, pour la préparation d'une formulation selon la présente invention, destinée à traiter le déficit sébacé. L'invention a encore pour objet l'utilisation d'un principe actif choisi parmi les hormones stéroïdiennes, par exemple les œstrogènes, la progestérone ou les antiandrogènes tels que la cyprotérone ou le finastéride, pour la préparation d'une formulation selon la présente invention, destinée à traiter la maladie de Fox et Fordyce, l'alopécie androgenique ou l' hirsutisme. L'invention a enfin pour objet l'utilisation d'un principe actif choisi parmi les céramides ou leurs précurseurs tels qu'une base sphingoïde, par exemple la sphingosine, la sphinganine, la phytosphingosine, la tétracétylphytosphingosine, la N-acétylphytosphingosine, le chlorhydrate de phytosphingosine et le salicylate de phytosphingosine, pour la préparation d'une formulation selon la présente invention, destinée à traiter les folliculites chroniques du cuir chevelu.
L'invention a pour objet l'utilisation d'un principe actif choisi parmi les acides gras essentiels par exemple l'acide linoleique et l'acide linolénique, pour la préparation d'une formulation selon la présente invention, destinée à traiter l'ichtyose dans sa localisation du cuir chevelu. En dernier lieu, l'invention a pour objet l'utilisation d'un principe actif choisi parmi les esters d'acide kojique, par exemple le dipalmitate d'acide kojique ; les extraits de licorice (glabridine) ; les hormones stéroïdiennes, par exemple les œstrogènes, la progestérone et les antiandrogènes ; la vitamine A, par exemple l'acétate de rétinyle, le palmitate de rétinyle, l'acide rétinoïque, le rétinaldéhyde et le β-carotène ; les céramides ou leurs précurseurs tels qu'une base sphingoïde, par exemple la sphingosine, la sphinganine, la phytosphingosine, la tétracétylphytosphingo- sine, la N-acétylphytosphingosine, le chlorhydrate de phytosphingosine et le salicylate de phytosphingosine, destinée à traiter les lentigos actiniques, les troubles pigmentaires liés au vieillissement et l' hypermélanose . Les exemples qui suivent illustrent la présente invention, sans toutefois en limiter la portée.Application of the formulation The formulations according to the invention are extremely effective for long periods of time in the various treatments described above. The formulations according to the present invention can be packaged in bottles with suitable applicators. Typically the formulation can be applied in the form of one or more drops to be distributed over the areas to be treated. The dosage is adapted according to the active ingredient used and the condition to be treated. For example, it can be between 10 and 25 drops applied to the face, in the case of retinoic acid in 0.5% solution. It can also be noted that the flow of the sebum excretion phase depends on the temperature. This parameter can be advantageously used when seeking to administer a lipophilic anti-radical agent. Indeed, the temperature having a fluidifying effect on the sebum, the anti-free radical agent can be released more quickly when the skin is exposed to the sun. Use of the formulation The invention relates to a method of cosmetic treatment of the skin intended for the treatment or prevention of skin damage associated with aging of the skin which may consist of a loss of firmness of the skin, of the skin tone and the appearance of fine lines and wrinkles, consisting in applying to the affected areas of the skin a formulation according to the present invention containing vitamin A, for example in the form of retinyl acetate, retinyl palmitate, retinoic acid, retinaldehyde or β-carotene. The invention also relates to a cosmetic treatment method for the skin intended for the treatment or prevention of skin damage associated with photoaging of the skin, comprising applying to the affected areas of the skin a formulation according to the present invention containing vitamin A, for example in the form of retinyl acetate, retinyl palmitate, retinoic acid, retinaldehyde or β-carotene, vitamin E, for example in the form of tocopherol acetate or tocopherol succinate, or any lipophilic anti-free radical agent, for example in the form of lipoic acid, andro-grapholides, esters of vitamin C such as palmitate and ascorbyl stearate. In addition, the invention relates to a method of cosmetic treatment of the skin intended for exfoliation or peeling thereof, consisting in applying to the skin a formulation according to the present invention containing concentrated retinoic acid, preferably between 0, 1 and 1%. In addition, the invention relates to a spot-on type formulation according to the present invention for its use as a dermatological composition for human medicine. More particularly, the invention relates to: - a spot-on type formulation according to the present invention, comprising vitamin A, a steroid hormone dienne, a ceramide or one of its precursors of sphingoid base type or else an essential fatty acid, for its use as a dermatological composition intended for treating acne, - a formulation of spot-on type according to the present invention, comprising a ceramide or one of its precursors of sphingoid base type or else a steroid hormone, for its use as a dermatological composition intended for treating seborrhea, - a formulation of spot-on type according to the present invention, comprising a ceramide or one of its sphingoid base precursors or an essential fatty acid, for its use as a dermatological composition intended for treating seborrheic dermatitis, - a formulation of spot-on type according to the present invention, comprising vitamin E , vitamin A or glycerol, for its use as a dermatological composition intended to treat sebaceous deficit, - a formulation of spot-on type according to the present invention, comprising a steroid hormone for anti-inflammatory purposes, for its use as a dermatological composition intended to treat Fox and Fordyce disease, or an anti-androgenic hormonal substance in the context of androgenic alopecia and hirsutism, - a spot-on formulation according to the present invention, comprising a ceramide or one of its precursors of sphingoid base type, for its use as a dermatological composition intended for treating chronic folliculitis of leather scalp, - a spot-on type formulation according to the present invention, comprising an essential fatty acid, for its use as a dermatological composition intended for treating ichthyosis in its localization in the scalp. a spot-on type formulation according to the present invention, comprising a kojic acid ester, a licorice extract, a steroid hormone, vitamin A or else a ceramide or one of its sphingoid base type precursors, for its use as a dermatological composition intended to treat actinic lentigos, pigmentary disorders linked to aging and hypermelanosis. In addition, the invention relates to the use of a lipophilic active principle for cutaneous use for the preparation of a formulation for localized topical application in humans, intended to be absorbed by the sebaceous glands and then gradually released into the time by the latter on the stra tum corneum, according to its secretory flow. The invention relates to the use of an active principle chosen from vitamin A, for example in pure form (retinol) or in the form of retinyl acetate, palmitate or retinyl of retinoic acid, retinaldehyde or β - carotene; steroid hormones, for example estrogens, progesterone and antiandrogens; ceramides or their precursors such as sphingoid bases, for example sphingosine, sphinganine, phytosphingosine, tetracetylphytosphingosine, N-acetylphytosphingosine, phytosphingosine hydrochloride and phytosphingosine salicylate; essential fatty acids, for example linoleic acid and linolenic acid, for the preparation of a formulation according to the present invention, intended for treating acne. In addition, the invention relates to the use of an active principle chosen from ceramides or their precursors such as sphingoid bases, for example sphingosine, sphinganine, phytosphingosine, tetracetylphytosphingosine, N-acetylphytosphingosine, hydrochloride phytosphingosine and phytosphingosine salicylate; steroid hormones such as estrogen, progesterone or antiandrogens, for the preparation of a formulation according to the present invention, intended for treating seborrhea. The invention also relates to the use of an active principle chosen from ceramides or their precursors such as a sphingoid base, for example sphingosine, sphinganine, phytosphingosine, tetracetylphytosphingosine, N-acetylphytosphingosine, phytosphingosine hydrochloride and phytosphingosine salicylate; essential fatty acids, for example linoleic acid and linolenic acid, for the preparation of a formulation according to the present invention, intended for treating seborrheic dermatitis. In addition, the invention relates to the use of an active ingredient chosen from vitamin E, for example tocopherol acetate, tocopherol succinate; vitamin A, for example retinyl acetate, retinyl palmitate, retinoic acid, retinaldehyde or β-carotene and glycerol, for the preparation of a formulation according to the present invention, intended for treating deficit sebaceous. Another subject of the invention is the use of an active principle chosen from steroid hormones, for example estrogens, progesterone or antiandrogens such as cyproterone or finasteride, for the preparation of a formulation according to the present invention , intended to treat Fox and Fordyce disease, androgenic alopecia or hirsutism. The invention finally relates to the use of an active principle chosen from ceramides or their precursors such as a sphingoid base, for example sphingosine, sphinganine, phytosphingosine, tetracetylphytosphingosine, N-acetylphytosphingosine, hydrochloride of phytosphingosine and phytosphingosine salicylate, for the preparation of a formulation according to the present invention, intended for treating chronic folliculitis of the scalp. The subject of the invention is the use of an active principle chosen from essential fatty acids, for example linoleic acid and linolenic acid, for the preparation of a formulation according to the present invention, intended for treating ichthyosis in its location of the scalp. Finally, the subject of the invention is the use of an active ingredient chosen from kojic acid esters, for example kojic acid dipalmitate; licorice extracts (glabridin); steroid hormones, for example estrogens, progesterone and antiandrogens; vitamin A, for example retinyl acetate, retinyl palmitate, retinoic acid, retinaldehyde and β-carotene; ceramides or their precursors such as a sphingoid base, for example sphingosine, sphinganine, phytosphingosine, tetracetylphytosphingosine, N-acetylphytosphingosine, phytosphingosine hydrochloride and phytosphingosine salicylate, intended for treating actinic lentigos pigmentary disorders linked to aging and hypermelanosis. The examples which follow illustrate the present invention, without however limiting its scope.
Exemple 1 : Protocole d'étude et résultat (10 cas) pour la vitamine A Ce premier exemple a pour but d' illustrer la pertinence du concept d'administration de principes actifs lipophiles dans les réservoirs folliculaires préalablement à leur libération prolongée, selon le cycle physiologique. Pour affirmer ce concept :Example 1: Study Protocol and Result (10 Cases) for Vitamin A This first example aims to illustrate the relevance of the concept of administration of lipophilic active principles in the follicular reservoirs before their prolonged release, according to the cycle physiological. To affirm this concept:
- La vitesse d'absorption de l'actif après application locale a été déterminée,- The absorption speed of the active ingredient after local application has been determined,
- Son stockage préférentiel au niveau de l'unité pilosebacée a été vérifié,- Its preferential storage at the pilosebaceous unit has been verified,
- Son relargage progressif et continu et sa durée ont été contrôlés .
Une méthodologie originale a été utilisée. Un certain nombre de lipides fluorescents ayant une compatibilité avec les lipides sébacés ont été sélectionnés. La peau a été exposée à une lampe de Wood. On a ainsi déterminé la surface de dispersion après application d'une dose unique de la solution à étudier (« effet cracking ») . On a également effectué des mesures de vitesse d'absorption par la glande sébacée. Selon un protocole particulier pour chaque principe actif considéré, la réalité du relargage a été démontrée par fluorescence simple. Une approche plus quantitative a également pu être mise en place grâce au Sebutest, qui est destiné à mesurer le flux sébacé et à collecter le sébum pour analyse. Ces paramètres permettent de prévoir la durée d'action de l'actif et par conséquent la posologie à recommander. Il a également été tenu compte des variations du nombre de glandes sébacées selon la topographie en effectuant les études sur des sites différents. Ceci a permis de moduler la posologie en fonction du site d'application, de même la réponse selon l'âge a été évaluée.- Its gradual and continuous release and its duration have been controlled. An original methodology was used. A number of fluorescent lipids having compatibility with sebaceous lipids were selected. The skin was exposed to a Wood lamp. The dispersion surface was thus determined after application of a single dose of the solution to be studied ("cracking effect"). Rate of absorption by the sebaceous gland was also measured. According to a specific protocol for each active ingredient considered, the reality of salting out has been demonstrated by simple fluorescence. A more quantitative approach has also been implemented thanks to the Sebutest, which is intended to measure the sebaceous flow and to collect the sebum for analysis. These parameters make it possible to predict the duration of action of the active ingredient and therefore the dosage to be recommended. Variations in the number of sebaceous glands according to the topography were also taken into account when carrying out studies on different sites. This made it possible to adjust the dosage according to the application site, and the response according to age was evaluated.
MISE EN ŒUVRE : Une étude comparative a été menée sur deux formulations (une formulation témoin et une formulation selon l'invention)IMPLEMENTATION: A comparative study was carried out on two formulations (a control formulation and a formulation according to the invention)
PREPARATION : Palmitate de vitamine A 3000000 UI BHT 0,10 g PVP 4 g BHA 0,20 g Fluorescéinate de sodium 020 g (ou rouge du nil 0,20 g) Acide linoleique 5 g Diéthylène glycol QS 100 g
TEMOIN : Fluorescéinate de sodium 0,20 g Alcool 60° QS 100 gPREPARATION: Vitamin A palmitate 3,000,000 IU BHT 0.10 g PVP 4 g BHA 0.20 g Sodium fluoresceinate 020 g (or nile red 0.20 g) Linoleic acid 5 g Diethylene glycol QS 100 g WITNESS: Sodium Fluoresceinate 0.20 g Alcohol 60 ° QS 100 g
CHOIX DES SITES D'APPLICATION : Région riche en glandes sébacées : pli sus-mentonnier, plis nasogenienCHOICE OF APPLICATION SITES: Region rich in sebaceous glands: above-mentioned fold, nasogenic fold
Région moins riche : avant bras (face antérieure) Région pileuse : cuir cheveluLess rich region: forearm (anterior side) Hair region: scalp
PROTOCOLE : Une étude comparative a été menée sur des zones symétriques. On a déposé sur chaque zone retenue une goutte de 0,4 ml du produit à étudier. On a procédé au séchage naturel sans étalement. On a étudié - la dispersion par mesure de la surface couverte après 15 minutes - l'absorption par degré de fluorescence à 60 minutes et à 6 heures - la rémanence par mesure de la fluorescence à 24 heures, 48 heures, 96 heures. A la 168ème heure, la toilette de la peau ou du cuir chevelu se faisait normalement en évitant toutefois des tensioactifs trop puissants. Un pain de toilette surgras et un shampooing doux ont été recommandés. On a également étudié l'extinction de la fluorescence. On a mis en évidence l'actif par stripping de l'épiderme et coloration spécifique par le trichlorure d'antimoine qui donne une coloration bleue en microscopie à 24 heures et 96 heures. Enfin, on a étudié le spectre d'absorption (bande caractéristique à 328 nanomètres) .PROTOCOL: A comparative study was carried out on symmetrical zones. A drop of 0.4 ml of the product to be studied was deposited on each zone retained. Natural drying was carried out without spreading. We studied - the dispersion by measuring the area covered after 15 minutes - the absorption by degree of fluorescence at 60 minutes and 6 hours - the afterglow by measuring the fluorescence at 24 hours, 48 hours, 96 hours. At the 168 th hour, the toilet of the skin or the scalp was done normally while avoiding too powerful surfactants. A surgras toilet roll and a mild shampoo were recommended. The extinction of fluorescence has also been studied. The active has been demonstrated by stripping the epidermis and specific coloring with antimony trichloride which gives a blue coloring under microscopy at 24 hours and 96 hours. Finally, we studied the absorption spectrum (characteristic band at 328 nanometers).
RESULTATS : Les résultats sont identiques chez tous les sujets.
La dispersion est meilleure sur les zones pileuses et sur les zones riches en glandes sébacées, elle est dans tous les cas supérieure au témoin. L'absorption est identifiable dès la première heure avec un pointillé au niveau de la tache de dispersion correspondant aux orifices pilosébacés. Ce pointillé n'est pas retrouvé au niveau du témoin. Cet aspect s'amplifie à la 6èrae heure alors que la fluorescence de la tache témoin diminue. La rémanence est confirmée par une persistance nette de la fluorescence que l'on constate encore à la 168ème heure. On constate une disparition totale de la tache témoin, la rémanence est plus importante sur les zones riches en glandes sébacées . Par conséquent, la présence de la vitamine A a été confirmée au 4ème jour sur toutes les zones et au 7ème jour sur les zones pileuses . L'extinction de la fluorescence est supérieure à un délai de 9 jours. Exemple 2 : Formulation d'acide rétinoïque dans une formulation selon l'invention Acide rétinoïque 0,30 g BHT 0,10 g BHA 0,20 g Acide linoleique 5,00 g PVP 4,00 g Transcutol QS 100 gRESULTS: The results are identical in all subjects. The dispersion is better on the hairy areas and on the areas rich in sebaceous glands, it is in all cases greater than the control. The absorption is identifiable from the first hour with a dotted line at the level of the dispersion spot corresponding to the pilosebaceous orifices. This dotted line is not found at the witness level. This aspect is amplified at the 6 th hour while the fluorescence of the control spot decreases. The remanence is confirmed by a clear persistence of the fluorescence which is still observed at the 168 th hour. There is a total disappearance of the control spot, the remanence is greater on the areas rich in sebaceous glands. Therefore, the presence of vitamin A has been confirmed in the 4 th day on all areas and at day 7 on hairy areas. The extinction of the fluorescence is greater than a period of 9 days. Example 2: Retinoic acid formulation in a formulation according to the invention Retinoic acid 0.30 g BHT 0.10 g BHA 0.20 g Linoleic acid 5.00 g PVP 4.00 g Transcutol QS 100 g
Etude d'efficacité et de tolérance versus solution Locacid® à 0,1% 5 patients ont reçu la formulation spot-on, les 5 autres du Locacid®, le produit a été appliqué sur le front, les joues, les ailes du nez et le menton : 1 seule application
pour la formulation spot on, 1 application journalière pour le Locacid®. Les observations ont été faites à Jl, J2, J3, J4 , J5, J6 et J8. Les types de peaux étaient identiques, à savoir normales à tendance grasse, les patients étaient âgés de 35 à 50 ans. Chez les patients traités au Locacid® on constate dès J2 des phénomènes irritatifs avec rougeur, sensation de brûlure et dessèchement. L'arrêt du traitement a été indispensable après la 3ème application dans 4 cas sur 5 et au 4ème jour pour le 5ème patient. Chez les patients traités par la formulation spot-on, on constate une activité progressive, sans phénomènes irritatifs, et visible sous forme d'une fine desquamation qui débute au 3ème jour pour se prolonger jusqu'au 6ème jour et une amélioration globale de la surface cutanée. Cette étude démontre que la formulation spot-on de l'invention est supérieure au Locacid®, que l'action est progressive et qu'elle s'étale sur 8 jours dans des conditions de tolérance remarquable, permettant de pouvoir juger les effets réels du produit. Ces constatations permettent de proposer un nouveau mode d'administration de la vitamine A acide (acide rétinoïque), beaucoup plus performant que les propositions connues dispo- nibles. La facilité de traitement avec une seule application par semaine est un gage d'observance.Efficacy and tolerance study versus 0.1% Locacid® solution 5 patients received the spot-on formulation, the other 5 of Locacid®, the product was applied to the forehead, cheeks, nose wings and chin: only 1 application for the spot on formulation, 1 daily application for Locacid®. The observations were made on D1, D2, D3, D4, D5, D6 and D8. The skin types were identical, namely normal to oily tendency, the patients were between 35 and 50 years old. In patients treated with Locacid®, irritative phenomena with redness, burning sensation and dryness are noted from D2. Stopping treatment was necessary after the 3rd application in 4 of 5 cases and 4 th day for the 5th patient. In patients treated by the spot-on formulation, a gradual activity is found, without irritative phenomena, and visible as a fine peeling starting day 3 to extend to the 6th day and an overall improvement of the skin surface. This study demonstrates that the spot-on formulation of the invention is superior to Locacid®, that the action is progressive and that it is spread over 8 days under conditions of remarkable tolerance, allowing us to be able to judge the real effects of the product. These findings make it possible to propose a new mode of administration of vitamin A acid (retinoic acid), much more effective than the known proposals available. The ease of treatment with a single application per week is a guarantee of compliance.
Exemple 3 : Autres exemples de formulations selon l'invention et résultats après traitement D' autres exemples ont été menés pour illustrer la variété de traitements pouvant être envisagés grâce aux formulations selon la présente invention.
Spot-on à base d'acide linoleique 2 applications par semaine pour traiter l'acné rétention- nelle. But : correction des déficits en acide linoleique dans le sébum des patients acnéiques. Les résultats se sont avérés très positifs.Example 3: Other examples of formulations according to the invention and results after treatment Other examples have been carried out to illustrate the variety of treatments which can be envisaged by means of the formulations according to the present invention. Spot-on based on linoleic acid 2 applications per week to treat retentional acne. Aim: correction of deficits in linoleic acid in the sebum of acne patients. The results have been very positive.
Spot-on à base de phytosphingosine et d'acide linoleique versus ketoconazole et corticoïdes locaux dans la prise en charge de la dermite séborrhéique. La formulation utilisée était la suivante : Salicyloyl phytosphingosine 0,5 G Tocopherol 0,5 G Triglycéride C8-C10 caprylique caprique 10,0 ML Ethanol 13,5 ML PVP 5,0 G TWEEN 80 5,0 G TRANSCUTOL 60 ML Propylène glycol QS 100 ML 2 applications par semaine contre une application journalière du ketoconazole et des corticoïdes locaux. Les résultats se sont avérés très positifs. En effet, l'efficacité de la formulation Spot-on a été plus rapide que celle à base de ketoconazole et de corticoïdes locaux. Ainsi, le sevrage des corticoïdes a pu être facilité. Par ailleurs, on n'observe pas de rebond à l'arrêt du traitement.Spot-on based on phytosphingosine and linoleic acid versus ketoconazole and local corticosteroids in the management of seborrheic dermatitis. The formulation used was as follows: Salicyloyl phytosphingosine 0.5 G Tocopherol 0.5 G Triglyceride C8-C10 caprylic capric 10.0 ML Ethanol 13.5 ML PVP 5.0 G TWEEN 80 5.0 G TRANSCUTOL 60 ML Propylene glycol QS 100 ML 2 applications per week against a daily application of ketoconazole and local corticosteroids. The results have been very positive. Indeed, the effectiveness of the Spot-on formulation was faster than that based on ketoconazole and local corticosteroids. Thus, the withdrawal of corticosteroids could be facilitated. Furthermore, no rebound was observed when the treatment was stopped.
Spot-on à base de phytosphingosine et d'acide linolenique dans les folliculites chroniques du cuir chevelu La formulation utilisée était la suivante : Chlorhydrate de phytosphingosine 0,4 G Acide gamma linolenique 5,0 G Ethanol 20 ML TRANSCUTOL QS 100 ML 2 applications par semaine.
On a pu observer un résultat dès la 2ème semaine de traitement .Spot-on based on phytosphingosine and linolenic acid in chronic scalp folliculitis The formulation used was as follows: Phytosphingosine hydrochloride 0.4 G Linolenic gamma acid 5.0 G Ethanol 20 ML TRANSCUTOL QS 100 ML 2 applications per week. It was observed an outcome from the 2nd week of treatment.
Spot-on à base d'extrait de licorice et d'acide linoleique dans le traitement des lentigos actiniques La formulation utilisée était la suivante : PT40 (extrait de licorice) 0,80 G Acide linoleique 5,0 ML Dioléate de polyglycéryle 4,5 ML Ethanol 15,0 ML TRANSCUTOL 60,0 ML TWEEN 80 50,0 G PVP 5,0 G Propylène glycol QS 100 ML 1 application tous les 5 jours dans le traitement des lentigos actiniques de la face. On observe un éclaircissement notable après 4 semaines de traitement .Spot-on based on licorice extract and linoleic acid in the treatment of actinic lentigos The formulation used was as follows: PT40 (licorice extract) 0.80 G Linoleic acid 5.0 ML Polyglyceryl dioleate 4.5 ML Ethanol 15.0 ML TRANSCUTOL 60.0 ML TWEEN 80 50.0 G PVP 5.0 G Propylene glycol QS 100 ML 1 application every 5 days in the treatment of actinic lentigines of the face. A notable lightening is observed after 4 weeks of treatment.
Spot-on acide rétinoïque + acide palmitique dans le peeling versus AHA ou acide trichloracetique La formulation utilisée était la suivante : Acide rétinoïque 0,5 G Acide palmitique 4,0 G PVP 5,0 G BHT 0,1 G BHA 0,2 G TRANSCUTOL QS 100 ML On a observé des résultats meilleurs qu' avec les alpha- hydroxyacides (AHA) et équivalents à l'acide trichloracetiqueSpot-on retinoic acid + palmitic acid in the peel versus AHA or trichloroacetic acid The formulation used was as follows: Retinoic acid 0.5 G Palmitic acid 4.0 G PVP 5.0 G BHT 0.1 G BHA 0.2 G TRANSCUTOL QS 100 ML Better results have been observed than with alpha-hydroxy acids (AHA) and equivalent to trichloroacetic acid
30% sans gène sociale ni trouble pigmentaire post peeling.30% without social gene or post-peeling pigmentary disorder.
Spot-on tocopherol + acide palmitoléique dans la protection solaire La formulation utilisée était la suivante : Alpha tocopherol 1,0 G
Acide palmitoléique 5,0 G TWEEN 80 50,0 G PVP 5,0 G Ethanol 10 ML TRANSCUTOL QS 100 ML 1 application par semaine. On observe un renforcement de la photoprotection naturelle .Spot-on tocopherol + palmitoleic acid in sun protection The formulation used was as follows: Alpha tocopherol 1.0 G Palmitoleic acid 5.0 G TWEEN 80 50.0 G PVP 5.0 G Ethanol 10 ML TRANSCUTOL QS 100 ML 1 application per week. There is an increase in natural photoprotection.
Spot-on acide linoleique dans l'icthyose du cuir chevelu 2 applications par semaine. Acide linoleique 5,0 G Tocopherol 0,5 G BHT 0,1 G BHA 0,2 G TWEEN 80 10,0 G Isopropanol 40 ML Diéthylène glycol QS 100 ML On observe une normalisation de l'état desquamatif.
Spot-on linoleic acid in ichthyosis of the scalp 2 applications per week. Linoleic acid 5.0 G Tocopherol 0.5 G BHT 0.1 G BHA 0.2 G TWEEN 80 10.0 G Isopropanol 40 ML Diethylene glycol QS 100 ML There is a normalization of the desquamative state.
Claims
1. Formulation de type spot-on pour l'application topique localisée, caractérisée en ce qu'elle comprend une emulsion ou solution saturée contenant un principe actif lipophile dans un mélange de solvants comprenant un ou plusieurs acides gras insaturés en C4-C26 et un véhicule liquide polaire, à tropisme sébacé. 1. Spot-on type formulation for localized topical application, characterized in that it comprises an emulsion or saturated solution containing a lipophilic active principle in a mixture of solvents comprising one or more unsaturated C 4 -C 26 fatty acids and a polar liquid vehicle, with a sebaceous tropism.
2. Formulation de type spot-on selon la revendication2. Spot-on type formulation according to claim
1, caractérisée en ce que le principe actif est choisi parmi la vitamine A ; la vitamine E ; un agent antiradicalaire lipophile ; les céramides ou les bases sphingoïdes ; et les hormones stéroïdiennes. 1, characterized in that the active principle is chosen from vitamin A; vitamin E; a lipophilic anti-radical agent; ceramides or sphingoid bases; and steroid hormones.
3. Formulation de type spot-on selon la revendication3. Spot-on type formulation according to claim
2, caractérisée en ce que la vitamine A se présente sous forme naturelle (rétinol) , sous forme de son acide (acide réti- noïque) ou encore d'acétate de rétinyle, de rétinaldéhyde, de β-carotène ou de palmitate de rétinyle ; la vitamine E se présente sous forme pure ou d'un ester tel que l'acétate de tocopherol, le linoléate de tocopherol ou le succinate de tocopherol ; l'agent radicalaire lipophile est choisi parmi les dérivés de l'acide α-lipoïque, les andrographolides, les dérivés lipophiles de la vitamine C tels que le palmitate et le stéarate d' ascorbyle ; la base sphingoïde est choisie parmi la sphingosine, la sphinganine, la phytosphingosine, la tétra- cétylphytosphingosine, la N-acétylphytosphingosine, le chlor- hydrate de phytosphingosine et le salicylate de phytosphingosine et les hormones stéroïdiennes sont choisies parmi les œstrogènes, les antiandrogènes et la progestérone. 2, characterized in that vitamin A is in natural form (retinol), in the form of its acid (retinoic acid) or else retinyl acetate, retinaldehyde, β-carotene or retinyl palmitate; vitamin E is present in pure form or of an ester such as tocopherol acetate, tocopherol linoleate or tocopherol succinate; the lipophilic radical agent is chosen from derivatives of α-lipoic acid, andrographolides, lipophilic derivatives of vitamin C such as palmitate and ascorbyl stearate; the sphingoid base is chosen from sphingosine, sphinganine, phytosphingosine, tetracetylphytosphingosine, N-acetylphytosphingosine, phytosphingosine hydrochloride and phytosphingosine salicylate and the steroid hormones are chosen from estrogens and antiestrogens, progesterone.
4. Formulation de type spot-on selon l'une quelconque des revendications 1 à 3, caractérisée en ce que l'acide gras insaturé en C4-C26 est choisi parmi l'acide sapienique, l'acide linolenique et l'acide linoleique. 4. Spot-on type formulation according to any one of claims 1 to 3, characterized in that the unsaturated C 4 -C 26 fatty acid is chosen from sapienic acid, linolenic acid and acid linoleic.
5. Formulation de type spot-on selon la revendication 4, caractérisée en ce que l'acide gras insaturé en C4-C26 est l'acide α- ou γ-linoléique. 5. A spot-on type formulation according to claim 4, characterized in that the unsaturated C 4 -C 26 fatty acid is α- or γ-linoleic acid.
6. Formulation de type spot-on selon l'une quelconque des revendications 1 à 5, caractérisée en ce qu'elle se présente sous forme d'une solution huileuse simple, d'une emulsion ou d'une emulsion de type quaternaire, saturées en principe actif. 6. formulation of spot-on type according to any one of claims 1 to 5, characterized in that it is in the form of a simple oily solution, of an emulsion or of an emulsion of quaternary type, saturated active ingredient.
7. Formulation de type spot-on selon l'une quelconque des revendications 1 à 6, caractérisée en ce qu'elle se présente sous forme d'une solution huileuse simple anhydre, saturée en principe actif et en ce que le véhicule liquide polaire comprend un solvant organique. 7. Formulation of the spot-on type according to any one of claims 1 to 6, characterized in that it is in the form of a simple anhydrous oily solution, saturated with active principle and in that the polar liquid vehicle comprises an organic solvent.
8. Formulation de type spot-on selon la revendication 7, caractérisée en ce que le solvant organique est choisi parmi l'acétone, l'acétate d'éthyle, le méthanol, l'éthanol, 1 ' isopropanol, le diméthylformamide, le diéthylène glycol, le dichloromethane, le 1, 2-O-isopropylidèneglycérol (Solketal) et le mono-éthyléther de diéthylène glycol (Transcutol) . 8. Spot-on type formulation according to claim 7, characterized in that the organic solvent is chosen from acetone, ethyl acetate, methanol, ethanol, isopropanol, dimethylformamide, diethylene glycol, dichloromethane, 1, 2-O-isopropylidene glycerol (Solketal) and the diethylene glycol monoethyl ether (Transcutol).
9. Formulation de type spot-on selon l'une quelconque des revendications 1 à 8 pour son utilisation à titre de composition dermatologique pour la médecine humaine. 9. A spot-on type formulation according to any one of claims 1 to 8 for its use as a dermatological composition for human medicine.
10. Utilisation d'un principe actif lipophile à visée cutanée pour la préparation d'une formulation pour l'appli- cation topique localisée chez l'homme destinée à être absorbée par les glandes sébacées puis relarguée progressivement dans le flux sébacé sur le stratum corneum, selon le rythme physiologique d'excrétion des glandes sébacées. 10. Use of a lipophilic active principle for cutaneous aiming for the preparation of a formulation for topical application localized in humans intended to be absorbed by the sebaceous glands and then gradually released into the sebaceous flow on the stratum corneum , according to the physiological rhythm of excretion of the sebaceous glands.
11. Utilisation d'un principe actif lipidique choisi parmi la vitamine A, les hormones stéroïdiennes, les céramides ou leurs précurseurs tels que les bases sphingoïdes et les acides gras essentiels, pour la préparation d'une formulation de type spot-on, destinée à traiter l'acné. 11. Use of a lipid active ingredient chosen from vitamin A, steroid hormones, ceramides or their precursors such as sphingoid bases and essential fatty acids, for the preparation of a spot-on type formulation intended for treat acne.
12. Utilisation d'un principe actif lipidique choisi parmi les céramides ou leurs précurseurs tels que les bases sphingoïdes et les hormones stéroïdiennes, pour la préparation d'une formulation de type spot-on, destinée à traiter la séborrhée. 12. Use of a lipid active principle chosen from ceramides or their precursors such as bases sphingoids and steroid hormones, for the preparation of a spot-on type formulation, intended to treat seborrhea.
13. Utilisation d'un principe actif lipidique choisi parmi les céramides ou leurs précurseurs tels qu'une base sphingoïde et les acides gras essentiels, pour la préparation d'une formulation de type spot-on, destinée à traiter la dermite séborrhéique. 13. Use of a lipid active principle chosen from ceramides or their precursors such as a sphingoid base and essential fatty acids, for the preparation of a spot-on type formulation intended for treating seborrheic dermatitis.
14. Utilisation d'un principe actif lipidique choisi parmi la vitamine E, la vitamine A et le glycerol, pour la préparation d'une formulation de type spot-on, destinée à traiter le déficit sébacé. 14. Use of a lipid active principle chosen from vitamin E, vitamin A and glycerol, for the preparation of a formulation of the spot-on type, intended to treat the sebaceous deficit.
15. Utilisation d'un principe actif lipidique choisi parmi les hormones stéroïdiennes, pour la préparation d'une formulation de type spot-on, destinée à traiter la maladie de Fox et Fordyce, l'alopécie androgenique ou l' hirsutisme. 15. Use of a lipid active principle chosen from steroid hormones, for the preparation of a spot-on formulation, intended to treat Fox and Fordyce disease, androgenic alopecia or hirsutism.
16. Utilisation d'un principe actif lipidique choisi parmi les céramides ou leurs précurseurs tels qu'une base sphingoïde, pour la préparation d'une formulation de type spot-on, destinée à traiter les folliculites chroniques du cuir chevelu. 16. Use of a lipid active principle chosen from ceramides or their precursors such as a sphingoid base, for the preparation of a spot-on type formulation intended for treating chronic folliculitis of the scalp.
17. Utilisation d'un principe actif lipidique choisi parmi les acides gras essentiels, pour la préparation d'une formulation de type spot-on, destinée à traiter l'ichtyose du cuir chevelu. 17. Use of a lipid active ingredient chosen from essential fatty acids, for the preparation of a spot-on type formulation intended for treating ichthyosis of the scalp.
18. Utilisation d'un principe actif lipidique choisi parmi les esters d'acide kojique, un extrait de licorice, les hormones stéroïdiennes, la vitamine A, les céramides ou leurs précurseurs tels qu'une base sphingoïde, pour la préparation d'une formulation de type spot-on, destinée à traiter les lentigos actiniques, les troubles pigmentaires liés au vieillissement et l' hypermélanose. 18. Use of a lipid active principle chosen from kojic acid esters, licorice extract, steroid hormones, vitamin A, ceramides or their precursors such as a sphingoid base, for the preparation of a formulation Spot-on type, intended to treat actinic lentigos, pigmentary disorders linked to aging and hypermelanosis.
19. Utilisation selon l'une quelconque des revendications 10 à 18, caractérisée en ce que la formulation spot-on est suivant l'une quelconque des revendications 1 à 8. 19. Use according to any one of claims 10 to 18, characterized in that the spot-on formulation is according to any one of claims 1 to 8.
20. Méthode de traitement cosmétique de la peau, caractérisée en ce qu'elle consiste à appliquer sur les zones affectées de la peau une formulation de type spot-on selon l'une quelconque des revendications 1 à 8. 20. Cosmetic treatment method for the skin, characterized in that it consists in applying to the affected areas of the skin a formulation of the spot-on type according to any one of claims 1 to 8.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0405136A FR2870125B1 (en) | 2004-05-12 | 2004-05-12 | FORMULATION OF THE SPOT-ON TYPE USEFUL IN COSMETOLOGY AND DERMATOLOGY |
PCT/FR2005/001188 WO2005115335A1 (en) | 2004-05-12 | 2005-05-12 | Spot-on formulation useful for cosmetology and dermatology |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1748758A1 true EP1748758A1 (en) | 2007-02-07 |
Family
ID=34948685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05770872A Withdrawn EP1748758A1 (en) | 2004-05-12 | 2005-05-12 | Spot-on formulation useful for cosmetology and dermatology |
Country Status (9)
Country | Link |
---|---|
US (1) | US20090010968A1 (en) |
EP (1) | EP1748758A1 (en) |
JP (1) | JP2007537214A (en) |
KR (1) | KR20070026580A (en) |
BR (1) | BRPI0510806A (en) |
CA (1) | CA2562565A1 (en) |
FR (1) | FR2870125B1 (en) |
IL (1) | IL178889A0 (en) |
WO (1) | WO2005115335A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102159179B (en) * | 2008-08-06 | 2013-02-27 | 匹托斯株式会社 | Composition for prevention and treatment of alopecia or for hair growth |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2389630T3 (en) * | 2004-11-10 | 2012-10-29 | Hisamitsu Pharmaceutical Co., Inc. | Drugs for external use and adhesive patch |
US10022348B2 (en) | 2009-05-20 | 2018-07-17 | Sun Pharmaceutical Industries Limited | Topical solution of isotretinoin |
MX2011012233A (en) | 2009-05-20 | 2012-04-19 | Ranbaxy Lab Ltd | Topical retinoid solutions. |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
PT2782584T (en) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Natural combination hormone replacement formulations and therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
JP2017516768A (en) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | Natural combination hormone replacement therapy and therapy |
US10098894B2 (en) | 2014-07-29 | 2018-10-16 | Therapeuticsmd, Inc. | Transdermal cream |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
KR102644587B1 (en) | 2015-12-24 | 2024-03-07 | (주)아모레퍼시픽 | Pseudoceramide compounds and preparation method thereof |
WO2017111387A1 (en) * | 2015-12-24 | 2017-06-29 | (주)아모레퍼시픽 | Pseudo-ceramide compound and preparation method therefor |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
KR20180126582A (en) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | Steroid hormone pharmaceutical composition |
WO2019002367A1 (en) * | 2017-06-28 | 2019-01-03 | Spherium Biomed, S.L. | Topical compositions for the treatment of dermatological diseases |
CN107714937A (en) * | 2017-12-12 | 2018-02-23 | 青岛大学附属医院 | It is a kind of to be used to treat instant particles as Chinese medicine of asteatosis and preparation method thereof |
AU2019230097B2 (en) * | 2018-03-09 | 2021-10-28 | Ocusoft, Inc. | Topical skin care compositions |
KR102592150B1 (en) * | 2020-07-09 | 2023-10-20 | 크로다코리아 주식회사 | Novel sphingolipid containing salicylic acid derivatives and composition comprising the same |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3025889A (en) * | 1988-03-08 | 1989-09-14 | Warner-Lambert Company | Compositions with enhanced penetration |
WO1990003163A1 (en) * | 1988-09-22 | 1990-04-05 | University Of Florida | Composition and method for enhancing permeability of topical drugs |
DE4407742C1 (en) * | 1994-03-08 | 1995-06-22 | Hexal Pharma Gmbh | Transdermal patch for treating tumours |
WO1998050023A1 (en) * | 1997-05-09 | 1998-11-12 | Kligman Douglas E | Use of high dose retinoids for the treatment of skin disorders |
US6248805B1 (en) * | 1997-10-31 | 2001-06-19 | Hewlett-Packard Company | Ink-jet printing ink compositions having magnetic properties and specific core/shell binder |
WO2004064841A1 (en) * | 2003-01-23 | 2004-08-05 | Shire Holdings Ag | Formulation and methods for the treatment of thrombocythemia |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU78168A1 (en) * | 1977-09-22 | 1979-05-25 | F Genieyz | SKIN TREATMENT COMPOSITION AND PREPARATION METHOD |
US4612194A (en) * | 1984-02-15 | 1986-09-16 | Roshdy Ismail | Anti-rheumatic agents and their use |
JPH01110610A (en) * | 1987-10-22 | 1989-04-27 | Lion Corp | Preventive for pimple |
DE4113346A1 (en) * | 1991-04-24 | 1992-10-29 | Lang Erich | Aq. lotion for strengthening and regeneration of hair-growth - comprises ethanol@, phospholipid(s) (derived from soya bean oil) oil, and/or grease |
US6426333B1 (en) * | 1996-09-19 | 2002-07-30 | Merial | Spot-on formulations for combating parasites |
FR2795960B1 (en) * | 1999-07-05 | 2001-10-19 | Sanofi Elf | STABLE MICROEMULSIONS FOR THE DELIVERY OF FATTY ACIDS TO HUMANS OR ANIMALS, AND USE OF SUCH MICROEMULSIONS |
US6361806B1 (en) * | 2000-02-23 | 2002-03-26 | Michael P. Allen | Composition for and method of topical administration to effect changes in subcutaneous adipose tissue |
US6365138B1 (en) * | 2000-04-07 | 2002-04-02 | The Regents Of The University Of California | Compositions for metabolic protection and repair of lips |
-
2004
- 2004-05-12 FR FR0405136A patent/FR2870125B1/en not_active Expired - Fee Related
-
2005
- 2005-05-12 JP JP2007512289A patent/JP2007537214A/en active Pending
- 2005-05-12 CA CA002562565A patent/CA2562565A1/en not_active Abandoned
- 2005-05-12 KR KR1020067026165A patent/KR20070026580A/en not_active Application Discontinuation
- 2005-05-12 EP EP05770872A patent/EP1748758A1/en not_active Withdrawn
- 2005-05-12 BR BRPI0510806-3A patent/BRPI0510806A/en not_active IP Right Cessation
- 2005-05-12 US US11/596,334 patent/US20090010968A1/en not_active Abandoned
- 2005-05-12 WO PCT/FR2005/001188 patent/WO2005115335A1/en active Application Filing
-
2006
- 2006-10-26 IL IL178889A patent/IL178889A0/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3025889A (en) * | 1988-03-08 | 1989-09-14 | Warner-Lambert Company | Compositions with enhanced penetration |
EP0499662A1 (en) * | 1988-03-08 | 1992-08-26 | Warner-Lambert Company | Compositions with enhanced penetration |
WO1990003163A1 (en) * | 1988-09-22 | 1990-04-05 | University Of Florida | Composition and method for enhancing permeability of topical drugs |
DE4407742C1 (en) * | 1994-03-08 | 1995-06-22 | Hexal Pharma Gmbh | Transdermal patch for treating tumours |
WO1995024187A1 (en) * | 1994-03-08 | 1995-09-14 | Hexal Ag | Plaster-shaped transdermal system with a tamoxifen derivative |
WO1998050023A1 (en) * | 1997-05-09 | 1998-11-12 | Kligman Douglas E | Use of high dose retinoids for the treatment of skin disorders |
US6248805B1 (en) * | 1997-10-31 | 2001-06-19 | Hewlett-Packard Company | Ink-jet printing ink compositions having magnetic properties and specific core/shell binder |
WO2004064841A1 (en) * | 2003-01-23 | 2004-08-05 | Shire Holdings Ag | Formulation and methods for the treatment of thrombocythemia |
Non-Patent Citations (1)
Title |
---|
See also references of WO2005115335A1 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102159179B (en) * | 2008-08-06 | 2013-02-27 | 匹托斯株式会社 | Composition for prevention and treatment of alopecia or for hair growth |
Also Published As
Publication number | Publication date |
---|---|
FR2870125B1 (en) | 2010-03-26 |
WO2005115335A1 (en) | 2005-12-08 |
US20090010968A1 (en) | 2009-01-08 |
BRPI0510806A (en) | 2007-11-06 |
JP2007537214A (en) | 2007-12-20 |
IL178889A0 (en) | 2007-03-08 |
KR20070026580A (en) | 2007-03-08 |
FR2870125A1 (en) | 2005-11-18 |
CA2562565A1 (en) | 2005-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005115335A1 (en) | Spot-on formulation useful for cosmetology and dermatology | |
EP1765356B1 (en) | Spray composition comprising a combination of calcitriol and clobetasol propionate, an alcoholic phase, at least one volatile silicone and one non volatile oily phase | |
EP1641463B1 (en) | Compositions in the form of a spray comprising a pharmaceutical agent at least one volatile silicone and a non-volatile oily phase | |
EP1758591B2 (en) | Invert emulsion composition containing calcitriol and clobetasol 17-propionate, and uses thereof in cosmetics and dermatology | |
EP1758588B1 (en) | Pharmaceutical composition comprising an ointment and two solubilized active principles | |
EP1648569B1 (en) | Cosmetic use of a composition containing at least one oxazoline, serving as an active substance, as a slimming product and/or for preventing and/or treating cellulite | |
FR2871698A1 (en) | SPRAY COMPOSITION COMPRISING AN ASSOCIATION OF PHARMACEUTICAL ASSETS AND AN OILY PHASE | |
WO2008087348A2 (en) | Emulsion comprising at least one retinoid and benzoyl peroxide | |
EP1269986A2 (en) | Compositions comprising a compound of low solubility and a lipophilic amino acid derivative, and corresponding uses and processes | |
CA2568262A1 (en) | Hydroalcoholic depigmentation gel comprising mequinol and adapalene | |
FR2674127A1 (en) | COSMETIC COMPOSITION FOR COMBATING AGING OF SKIN CONTAINING IN ASSOCIATION AT LEAST ONE RETINOUID AND AT LEAST ONE DIALKYL OR TRIALKYLXANTHINE. | |
FR2885050A1 (en) | Slimming cosmetic and/or pharmaceutical composition, useful for treatment of adipocytes of skin, comprises cocoa extract containing polyphenols | |
EP3355859A1 (en) | No-rinse chemical foam containing trifarotene, and use thereof in the treatment of ichthyosis | |
EP2114387B1 (en) | Use of compositions containing at least one lignane and/or neolignane for modulating testosterone levels | |
WO2018172379A1 (en) | Use of a copaifera extract to combat alopecia and seborrhea | |
EP2872116A1 (en) | Dermatological composition including oleosomes and retinoids, method for preparing same and use thereof | |
FR2894474A1 (en) | Depigmenting composition in the form of hydroalcoholic gel, useful e.g. to prevent/treat dermatological disorders related to pigmentation disorders, comprises a phenolic derivative, a retinoid and a corticoid | |
FR2876909A1 (en) | Cosmetic and/or pharmaceutical composition, to prevent or treat adipose overloads and cellulitis, comprises a combination of one or more xanthinic bases and chaulmoogra oil and/or its components | |
EP3302421B1 (en) | Compositions comprising at least one dispersed active principle and lipid microcapsules | |
WO2016102402A1 (en) | Aqueous composition comprising a 4-(heterocycloalkyl)-benzene-1,3-diol compound, a c2-c4 monoalcohol, and a glycol | |
FR2811566A1 (en) | COMPOSITION, ESPECIALLY COSMETIC, CONTAINING DHEA AND / OR ITS PRECURSORS OR DERIVATIVES, AND A VITAMIN | |
FR3131216A1 (en) | SKIN CARE COMPOSITION | |
WO2020169935A1 (en) | Use of evodone or a derivative thereof as a cooling agent | |
EP2694028A2 (en) | Composition based on chaulmoogra oil and tribulus terrestris for skin pigmentation | |
FR2826272A1 (en) | Compositions, useful for depigmenting or bleaching hyperpigmented skin , comprise a compound of low solubility and a lipophilic amino acid derivative give stable emulsions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20061124 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: GIREX |
|
17Q | First examination report despatched |
Effective date: 20100324 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20151201 |